Lexaria Bioscience Corp. (OTCQX: LXRP) Breaking News -
September 25, 2018
Intangible Assets Power Growth, Acquisitions in the Pharmaceuticals Sector Delivery
New York, NY – September 25, 2018 – CannabisNewsWire News
Coverage:
Intangible assets such as patents increasingly dominate the global business
landscape, especially in the pharmaceutical sector.
-
Intangible assets are estimated to be worth trillions of dollars in the
United States alone.
-
These assets drive deals as companies acquire smaller patent holders.
-
In
growing sectors such as cannabis, smaller companies are rushing to establish
intangible assets ready for expected market growth.
Lexaria Bioscience Corp.'s (CSE:LXX) (OTCQX:LXRP)
is one of the leaders in the world of cannabis, with applications made for more
than 50 different patents and more to come. Technology company SoftBank Group
Corp ADR (OTC:SFTBY)
 powers
its business through acquiring intellectual property, most recently acquiring
chip maker ARM. Biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY)
spent hundreds of millions last year to access immune-system-based anti-cancer
medicine through an IFM Therapeutics acquisition. Roche Holding Ltd ADR
(Sponsored) (OTC:RHHBY) invested $1.7 billion in a similar deal for a cancer
drug. Some companies gobble up chains of others, such as GlaxoSmithKline PLC
(NYSE:GSK), which has undertaken eight multimillion-dollar acquisitions
since 2010.
To view an infographic of this editorial,
click here.
The Power of Intellectual Property
Intellectual property (IP) is now one of the most important parts of the global
economy. Copyrights, trademarks and patents are a vital weapon in the arsenal of
many businesses. For some companies, this is a secondary consideration, a way to
strengthen and protect their positions within their fields. For others, it’s
their entire focus — a way to dominate a sector or provide valuable returns.
The power of IP means that no part of the economy goes untouched. New industries
often arise off the back of new IP. Even when that’s not the case, the
development of new techniques and technologies frequently lead to the creation
of patents, as companies work to innovate and control techniques that give them
an edge over their competitors. For relatively new sectors, such as the cannabis
market, this means the sudden flourishing of IP and a race by companies to stake
their claim on these valuable assets. As a sector matures, so will its IP
market.
The Value of Intangible Assets
Patents are a big part of business for companies such as
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX:LXRP), for whom developing
and protecting new technology is fundamental to success. Whether it’s underlying
technology such as DehydraTECH, the company’s system for increasing the body’s
absorption of chemical compounds, or specific products derived from DehydraTECH,
such as TurboCBD, Lexaria’s success is founded on its distinctive IP.
IP is part of a wider sector of the economy
valued at trillions of dollars in the United States alone — intangible
assets. This is the wealth provided not by physical assets and the processes
that directly transform them but by less visible, more abstract resources. It
includes IP, whose value is often examined and measured, as well as
harder-to-pin-down elements
such as business processes and reputation.
These factors have always played a part in business, but their growing
recognition and analysis has led to the growth of companies whose main focus is
on intangible assets, from investment research firms and reinsurers to patent
licensing and enforcement companies.
Representing around a third of the U.S. economy, intangible assets are now
consciously analyzed and developed by virtually every business, even if they
don’t recognize the “intangible asset” label. Companies with a solid focus on
these areas can place themselves in positions of great strength.
Patents in a New Sector
The speed at which intangible assets can develop is well illustrated by
movements in the cannabis sector, where many of Lexaria’s patents apply.
The legal global cannabis market started to emerge only recently, thanks to a
handful of countries allowing medical marijuana. The market has started to
mature through a small but growing number of territories with legal markets for
recreational cannabis, as well as the separate management and licensing of
industrial hemp. Legal cannabis is now a multi-billion dollar business. Although
Lexaria’s technology has other profound drug delivery applications, cannabis is
where it looks set to have the most immediate impact.
This has led to a rush to control intangible assets around cannabis. It’s
noteworthy that
Chinese companies own more than half of the cannabis-related patents
registered with the World Intellectual Property Organization, even though the
cannabis trade remains illegal in China. China has a good eye for long-term
developments and is setting itself up to control a growing global trade.
Outside of China, Lexaria is one of the world’s biggest holders of cannabis
patents with eight patents already granted. The company
currently holds four patents in the United States and four in Australia,
covering aspects of its work to make beneficial drugs more palatable and
effective. In addition, the company has further patent applications in process
in over 40 countries as part of a concerted strategy to expand its patent
portfolio. This is made possible by the focused, tangible research and
development being carried out by the company and is ultimately driven by the
need to develop and control intangible assets.
Lexaria has disclosed it expects four more patents granted in 2018, bringing its
total to twelve. Of note, all twelve of these are within just a single patent
family – and Lexaria expects patent success across all nine families of its
current applications. Indeed the company recently revealed that it has seven
more patent families in the works. Lexaria’s goal is to have some 200 patents
pending or granted which, if achieved, could turn the organization into an IP
behemoth in the global cannabis industry.
The Value of Patents
The commercial value of patents, even those still pending
approval, can be extraordinary, reaching billions of dollars. In 2011,
Nortel sold 6,000 patents and patent applications for $4.5 billion. The
following year,
AOL sold 925 patents to Microsoft for more than a billion dollars. While
some companies develop patents purely to protect their work, others develop them
specifically to be sold.
This focus on intangible assets drives many mergers and acquisitions. The
Craftsy digital network developed online shows such as “Man about Cake” with a
focus on audience rather than immediate profit, leading to the company’s
acquisition by NBC Universal. The intangible assets of the company’s identity,
reputation and audience had become highly valuable in themselves.
Similar priorities can be seen on a far larger scale in
SoftBank’s $31.4 billion acquisition of chip designer ARM Holdings,
or roughly $7 million per patent or patent application. ARM’s revenues
were only $1.5 billion per year, but its 4,500 patents cover technology of
potentially incredible value. In just three years, the desire to control
patented drugs and processes in the healthcare sector overall resulted in
58 mergers and acquisitions with values of a billion dollars or more.
In Lexaria’s field of pharmaceuticals, patents are crucial, representing both
the outcome of years of R&D and also potential market share and control in the
emerging global cannabis business. Lexaria is attempting to own enough IP in the
global cannabis industry that patent royalty revenues begin to flow worldwide.
Because patents are among the most valuable assets a company can own, a small
investment in research now may pay off in a huge way in years to come. In a
sector with such huge growth potential as cannabis, Lexaria’s IP portfolio may
generate cash flows regardless of whether other companies intend to license the
technology or not; by owning core IP, other companies may be forced to pay
royalties. If Lexaria’s goal of owning hundreds of issued patents becomes a
reality, the company’s patent portfolio could have huge ramifications on its
valuation.
Powered by Intellectual Property
The acquisition of ARM by SoftBank Group Corp ADR (OTC:SFTBY) is only one
in a string of investments in intellectual property by this Japanese holding
company. Softbank’s main business is technology and the intellectual property
surrounding it. It has invested heavily in developing and acquiring
subsidiaries, providing a wide range of patents and associated processes. This
has driven recent developments from the company such as a blockchain-based
mobile payments service and barcode-based smart payments.
Biopharmaceutical company Bristol-Myers Squibb Company (NYSE:BMY) is
focused on developing and delivering innovative medicines, a mission that
inevitably involves the discovery and patenting of new techniques. The company
has recently made advances in the treatment of ailments such as plaque psoriasis
and acute lymphoblastic leukemia. In addition, In August of last year,
Bristol-Myers announced the acquisition of IFM Therapeutics, gaining access to
that company’s work in using immune responses to battle cancer.
Another big IP-related acquisition was the 2017 purchase of Igynta by Roche
Holding Ltd ADR (Sponsored) (OTCQX:RHHBY). The $1.7 billion deal gave Roche
access to a cancer drug then going through its testing phase. This move was seen
as reinforcing Roche’s position as a world leader in cancer drugs and also
protecting it from difficulties as its existing medicines fell out of patent
protection. For big drug companies, patents create a significant portion of
their value.
British drugs giant GlaxoSmithKline PLC (NYSE:GSK) has relied heavily on
acquisitions to ensure its place near the top of the pharmaceuticals industry.
Since the start of 2010, it has undertaken eight major acquisitions, averaging
one a year, paying from $70 million to $3 billion for each step forward.
With so much value placed on intangible assets, patents are fueling growth and
acquisitions worth billions of dollars. In the pharmaceutical sector and beyond,
patents definitely appear to be where the big money is.
For more information on Lexaria, please visit
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX:LXRP).
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our
news aggregation and syndication servers, (2)
CannabisNewsBreaks that summarize corporate news and information, (3)
enhanced press release services, (4) social media distribution and optimization
services, and (5) a full array of corporate communication solutions. As a
multifaceted financial news and content distribution company with an extensive
team of contributing journalists and writers, CNW is uniquely positioned to best
serve private and public companies that desire to reach a wide audience of
investors, consumers, journalists and the general public. CNW has an
ever-growing distribution network of more than 5,000 key syndication outlets
across the country. By cutting through the overload of information in today’s
market, CNW brings its clients unparalleled visibility, recognition and brand
awareness. CNW is where news, content and information converge.
Receive Text Alerts from CannabisNewsWire:
Text "Cannabis" to 21000
For more
information please visit
https://www.CannabisNewsWire.com
and or
https://CannabisNewsWire.News
Please see full
terms of use and disclaimers on the CannabisNewsWire website applicable to all
content provided by CNW, wherever published or re-published:
http://CNW.fm/Disclaimer
DISCLAIMER: CannabisNewsWire (CNW) is the source of the
Article and content set forth above. References to any issuer other than the
profiled issuer are intended solely to identify industry participants and do not
constitute an endorsement of any issuer and do not constitute a comparison to
the profiled issuer. FN Media Group (FNM) is a third-party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels. FNM is NOT affiliated with CNW or any
company mentioned herein. The commentary, views and opinions expressed in this
release by CNW are solely those of CNW and are not shared by and do not reflect
in any manner the views or opinions of FNM. Readers of this Article and content
agree that they cannot and will not seek to hold liable CNW and FNM for any
investment decisions by their readers or subscribers. CNW and FNM and their
respective affiliated companies are a news dissemination and financial marketing
solutions provider and are NOT registered broker-dealers/analysts/investment
advisers, hold no investment licenses and may NOT sell, offer to sell or offer
to buy any security.
The Article
and content related to the profiled company represent the personal and
subjective views of the Author, and are subject to change at any time without
notice. The information provided in the Article and the content has been
obtained from sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all such
information. None of the Author, CNW, FNM, or any of their respective
affiliates, guarantee the accuracy or completeness of any such information. This
Article and content are not, and should not be regarded as investment advice or
as a recommendation regarding any particular security or course of action;
readers are strongly urged to speak with their own investment advisor and review
all of the profiled issuer's filings made with the Securities and Exchange
Commission before making any investment decisions and should understand the
risks associated with an investment in the profiled issuer's securities,
including, but not limited to, the complete loss of your investment.
CNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and CNW and FNM undertake no obligation to update
such statements.
CannabisNewsWire (CNW) & NetworkNewsWire (NNW) are proud to be affiliated
partners of the Investor Brand Network (IBN)
About IBN
Over the past 10+ years we have consistently introduced new network brands,
each specifically designed to fulfil the unique needs of our growing client base
and services. Today, we continue to expand our branded network of highly
influential properties, leveraging the knowledge and energy of specialized teams
of experts to serve our increasingly diversified list of clients.
Please feel free to visit the Investor Brand Network (IBN)
http://www.InvestorBrandNetwork.com
Corporate
Communications Contact:
CannabisNewsWire (CNW)
Denver,
Colorado
www.CannabisNewsWire.com
303.498.7722
Office
Editor@CannabisNewsWire.net
Media Contact:
FN Media Group,
LLC
NNW@FinancialNewsMedia.com
+1-(954)345-0611
News Source:
CannabisNewsWire
Big Businesses Look for Healthier Alternatives to Smoking for Drug Delivery
New York, NY – August 15, 2018 – NetworkNewsWire News
Coverage:
Despite the scientifically established harmful health effects of smoking,
millions of people around the world still do it. Because of this, many large
companies are looking for healthier ways to deliver active ingredients from
tobacco and cannabis to people with a smoking habit.
-
More than a billion people around the world smoke tobacco or cannabis,
leading to 6 million deaths a year.
-
Companies in the tobacco and cannabis sectors are looking for alternative
delivery systems
-
Some alternatives may be more effective — and healthier — than smoking
Lexaria Bioscience Corp.'s (CSE:LXX) (OTCQX:LXRP) is one of the
companies looking at alternative solutions, using fatty acids to make a
pleasing, fast, effective delivery system for nicotine and cannabidiol (CBD).
Tobacco company Altria
Group,
Inc. (NYSE:MO) is creating lower-risk tobacco products and recently received
FDA approval for its latest offering. British American Tobacco Industries
p.l.c. ADR (NYSE:BTI) has created a tobacco heater that produces fumes
instead of smoke, reducing the potential harm from consumption. GW
Pharmaceuticals Plc (NASDAQ:GWPH) has produced a liquid CBD product that is
the first U.S. Food and Drug Administration-approved medicine of its type. Most
telling of all, Philip Morris International, Inc. (NYSE:PM) has announced
a long-term strategy to move away from smoking as the core delivery system for
its products — a huge step for a global tobacco giant.
Money in Smoking
Smoking habits are currently undergoing significant changes. Increased
awareness of the dangers of tobacco has led to a decrease in the popularity of
cigarette smoking in many parts of the world. Meanwhile, the legalization of
cannabis in a growing number of markets is turning marijuana smoking into big
business, taking it out of the hands of criminals and attracting innovative
pharmaceutical and bioscience companies.
But while the growth of the cannabis industry has been welcomed by many, it has
raised the same concerns faced by the tobacco industry. Whether cannabis users
are looking to benefit from its health-giving properties or to enjoy it as a
recreational drug, people who smoke it are exposing themselves to similar risks
as other smokers, including lung cancer. If the cannabis industry wants to keep
growing and the tobacco industry wants to avoid collapse, both need to find new
ways to deliver the benefits of their products while avoiding the proven risks
of disease.
Alternatives to Smoking
Lexaria Bioscience Corp.'s (CSE:LXX) (OTCQX:LXRP) solution
offers a viable alternative. Founded in its current form in 2014, Lexaria
may seem like a relative newcomer, but its technology is already providing leaps
forward. By focusing on delivery systems for existing compounds, including both
nicotine and the active ingredients found in cannabis, the company is developing
specialist solutions to serious health problems.
Lexaria’s main technology is DehydraTECH™. This provides an unusual means for
helping the human body absorb beneficial substances and drugs, based on the
recognition that many of these molecules are lipophilic, or fat soluble. By
combining the drug molecules with fatty acids, DehydraTECH provides a new way
for the drugs to enter the body.
Lipophilic compounds face a variety of challenges in entering the human body.
Isolated from other flavors, they often taste and smell bad, making them
off-putting to consume. Once they enter the body, human systems have trouble
absorbing them. The compounds are vulnerable to destruction in the stomach and
being filtered out by the liver. As a result, they have low bioavailability, or
the extent to which they’re used by the body.
Smoking, vaping and large-dose consumption are all ways of getting around this
problem. But DehydraTECH provides another way. It’s almost tasteless and
odorless, making it palatable for edibles. Being combined with fatty acids makes
it easier and faster for the body to aborb, with five to ten times greater
absorption through the intestine.
Consumption of active compounds through DehydraTECH has two big advantages.
First, the consumer avoids smoking and the damage and diseases to the lungs
associated with that. Second, the increased and more rapid bioavailability means
that a higher amount of the drug molecules are taken in. This reduces the amount
people need to consume to gain the benefits, whether medical or recreational.
For consumers, DehydraTECH may represent a potential step towards a healthier
lifestyle. And for investors, it’s a way to enter the tobacco and cannabis
markets while avoiding the harm associated with those products — an opportunity
to make money while maintaining a clean conscience and reputation.
Big News for Nicotine
Lexaria recently announced the results of its second in vivo study of
2018 evaluating the use of DehydraTECH as a nicotine delivery system. The
results proved the delivery of more nicotine, more quickly, than the positive
controls.
The study, which was carried out by a third-party laboratory, looked at the
absorption of nicotine delivered in an edible form via DehydraTECH. It found
that the method led to significantly greater absorption of nicotine: there was
90.2 percent greater absorption within the first 10 minutes using the
DehydraTECH system instead of the tested control. Speed of absorption is one of
the most important issues for non-inhalation forms of nicotine delivery, given
the rapidity with which smoking gets the drug into the body, so this is a strong
sign for the potential of DehydraTECH as a smoking alternative. Because it
delivers the nicotine so quickly, Lexaria’s technology could open the door to
entirely new forms of consumer products around the world.
Finding such an effective method for nicotine delivery may
be a huge step forward. Despite the efforts of health professionals, there are
currently 6 million deaths from the consequences of smoking reported around the
world every year. That number is expected to hit 8 million by 2030. A system
that delivers nicotine as quickly and effectively as smoking could be a huge
boon for people looking to quit, allowing its producers to tap into a US $680
billion international market, excluding China.
Working with Cannabis
Nicotine isn’t the only drug with which Lexaria has experienced recent
successes. It has also announced the results of a double-blind, randomized
clinical study using DehydraTECH to make cannabidiol (CBD) bioavailable in human
subjects, with considerable success.
Participants in the study took 90mg doses of Lexaria’s TurboCBDTM
product. This contains cannabidiol (CBD), an active ingredient in cannabis that
doesn’t produce the mind-altering “high” properties of marijuana’s
tetrahydrocannabinol (THC) compound. CBD in a specific form recently received
FDA approval to treat certain forms of seizure disorders and is in widespread
use in wellness products. TurboCBD is designed as a way to more quickly and
effectively deliver CBD and its beneficial effects.
As in the nicotine study, Lexaria’s technology delivered the CBD more quickly
and effectively than alternative delivery systems. Within 30 minutes, it had
delivered over 300 percent more CBD into the bloodstream, and it continued to
have a higher impact across a six-hour study.
The increasing legalization of cannabis and cannabis-derived medicine risks
increasing the number of smokers in the world. Because smoking serves as an
effective means for delivering medicinal chemicals into the bloodstream, it is
appealing to users. But by providing an effective alternative for delivery,
Lexaria is offering a possible method for users to benefit from CBD without
suffering from smoking’s side effects.
Following the success of these two studies, Lexaria may be the only pure-play
biotech public company option available for investors looking for opportunities
to help reduce harm in both the tobacco and cannabis industries. It’s a
significant possibility in a changing industry.
More Companies Exploring Alternatives to Smoking
With health concerns at the forefront of so many people’s minds, several
companies are looking for smoke-free ways for their consumers to enjoy tobacco
and cannabis.
One of the largest tobacco companies in the world, Altria Group, Inc. (NYSE:MO),
is exploring ways to reduce the risk inherent in tobacco. The company has been
working on modified risk tobacco products, a category of consumables that allows
a company to claim its products are safer while selling them in the United
States. In March, it
submitted its latest application for one of these products to the FDA. The
company has so far steered away from direct involvement in cannabis to avoid the
federally banned drug’s range of legal and PR complications.
British American Tobacco Industries p.l.c. ADR (NYSE:BTI) is trying to
make tobacco consumption healthier through the use of alternative delivery
systems. Its glo products heat tobacco rather than burning it. The resulting
vapor is approximately 90 to 95 percent less toxic than cigarette smoke, giving
smokers a healthier way to satisfy their nicotine cravings. With its
recent launch in Italy, glo is now available in seven countries.
On the cannabis side, GW Pharmaceuticals Plc (NASDAQ:GWPH) has recently
received FDA approval for a CBD-based drug that will be America’s first
plant-derived cannabinoid prescription medicine. Designed to tackle child-onset
epilepsy, it makes CBD available as a medicine for children in need of its
benefits and adds a CBD medicine to the market that doesn’t bring with it the
dangers of smoking.
Even Philip Morris International, Inc. (NYSE:PM), one of the most
evocative names in cigarette merchandising, is looking towards a smoke-free
future. The company has made a strategic decision to
move away from a reliance on smoking, finding ways to provide customers with
the satisfaction of tobacco without the harm smoke brings. It’s a shift that
could provide big opportunities for companies with smoke-free nicotine
technology to license.
These Fortune-500 tobacco companies are faced with vital and dramatic threats to
their traditional business model as smokers desperately search for less harmful
alternatives to cigarettes and governments increasingly restrict access to
cigarettes. In the past year alone, these companies have suffered billion-dollar
losses in their market caps as consumer preferences shift. This is clearly a
problem needing an immediate solution.
As hundreds of millions of people around the world maintain their smoking
habits, the harmful effects on their health and their neighbors’ health continue
to be a huge concern. Companies that can create safer alternatives could bring
great benefits and enormous profits from such innovations.
For more information on Lexaria, please visit
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX:LXRP).
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content
distribution company that provides (1) access to a network of wire services via
NetworkWire to reach all target markets, industries and demographics in the
most effective manner possible, (2) article and editorial syndication to 5,000+
news outlets (3), enhanced press release services to ensure maximum impact, (4)
social media distribution via the Investor Brand Network (IBN) to nearly 2
million followers, (5) a full array of corporate communications solutions, and
(6) a total news coverage solution with
NNW Prime. As a multifaceted organization with an extensive team of
contributing journalists and writers, NNW is uniquely positioned to best serve
private and public companies that desire to reach a wide audience of investors,
consumers, journalists and the general public. By cutting through the overload
of information in today’s market, NNW brings its clients unparalleled
visibility, recognition and brand awareness. NNW is where news, content and
information converge. For more information, please visit
https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the NetworkNewsWire website
applicable to all content provided by NNW, wherever published or re-published:
http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and
content set forth above. References to any issuer other than the profiled issuer
are intended solely to identify industry participants and do not constitute an
endorsement of any issuer and do not constitute a comparison to the profiled
issuer. FN Media Group (FNM) is a third-party publisher and news dissemination
service provider, which disseminates electronic information through multiple
online media channels. FNM is NOT affiliated with NNW or any company mentioned
herein. The commentary, views and opinions expressed in this release by NNW are
solely those of NNW and are not shared by and do not reflect in any manner the
views or opinions of FNM. Readers of this Article and content agree that they
cannot and will not seek to hold liable NNW and FNM for any investment decisions
by their readers or subscribers. NNW and FNM and their respective affiliated
companies are a news dissemination and financial marketing solutions provider
and are NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy any
security.
The Article and content related to the profiled company represent the personal
and subjective views of the Author, and are subject to change at any time
without notice. The information provided in the Article and the content has been
obtained from sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all such
information. None of the Author, NNW, FNM, or any of their respective
affiliates, guarantee the accuracy or completeness of any such information. This
Article and content are not, and should not be regarded as investment advice or
as a recommendation regarding any particular security or course of action;
readers are strongly urged to speak with their own investment advisor and review
all of the profiled issuer's filings made with the Securities and Exchange
Commission before making any investment decisions and should understand the
risks associated with an investment in the profiled issuer's securities,
including, but not limited to, the complete loss of your investment.
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and NNW and FNM undertake no obligation to update
such statements.
NetworkNewsWire (NNW) is affiliated with the Investor Brand Network (IBN).
About IBN
Over the past 10+ years we have consistently introduced new network brands,
each specifically designed to fulfil the unique needs of our growing client base
and services. Today, we continue to expand our branded network of highly
influential properties, leveraging the knowledge and energy of specialized teams
of experts to serve our increasingly diversified list of clients.
Please feel
free to visit the Investor Brand Network (IBN)
www.InvestorBrandNetwork.com
Corporate
Communications Contact:
NetworkNewsWire
(NNW)
New York, New
York
www.NetworkNewsWire.com
212.418.1217
Office
Editor@NetworkNewsWire.com
Media Contact:
FN Media Group,
LLC
NNW@FinancialNewsMedia.com
+1-(954)345-0611
News Source: NetworkNewsWire
Innovative Cannabis Delivery Technology Boosts Discovery, Momentum in Biotech
Sectors
New York, NY – April 24, 2018 – NetworkNewsWire News
Coverage: Most people who try to quit smoking cigarettes will fail.
Why? Scientific research shows that the overwhelming culprit is nicotine.
Nicotine holds such an addictive power over smokers, because it arrives in the
brain so quickly — smoking delivers nicotine even faster than an injection, one
researcher notes (http://nnw.fm/uunO1). While people know that smoking is a
preventable killer, they also know that
quitting
is far easier said than done. Nicotine replacement therapy (NRT) products such
as nicotine gums, lozenges, sprays, sublingual tablets and transdermal patches
dominate the multibillion-dollar global smoking cessation and nicotine
de-addiction market. However, all commercial forms of NRT have different levels
of efficacy and variable rates of nicotine absorption, as noted in an article
published by the National Institutes of Health (http://nnw.fm/BgcC7). Enter drug
delivery platform innovator
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP), which recently
announced a significant breakthrough in alternative nicotine delivery technology
that was first proven effective in cannabinoid or CBD delivery. Other
biotechnology companies conducting research in similar arenas include GW
Pharmaceuticals Plc (NASDAQ: GWPH), CV Sciences, Inc. (OTC: CVSI), 22nd Century
Group, Inc. (NYSE: XXII) and Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE).
Research Goals Beyond CBD
The latest research results announced by
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP) are significant for a
host of reasons and could have ramifications for other drug delivery methods as
well. In this specific study, Lexaria’s patented DehydraTECH™ delivery
technology was analyzed for use as a new nicotine delivery method. The company’s
proprietary technology improves the delivery of bioactive compounds and has
already shown to enhance the bioavailability of orally ingested cannabinoids (CBDs)
derived from cannabis, while also masking taste. Third-party labs have shown a
499 percent increase in CBD bio-absorption in human intestinal tissues, as the
company noted in a news release announcing a U.S. patent for DehydraTECH™
(http://nnw.fm/2WP8e). As such, it made sense to further analyze DehydraTECH’s
capabilities in terms of nicotine delivery.
Gathering Clinical Evidence
Lexaria’s study hypothesis was tested to prove that its DehydraTECH technology
would influence more rapid and complete intestinal bioabsorption of ingestible
(edible) nicotine lymphatically with less metabolic degradation by the liver.
The study, conducted by the same independent laboratory that completed Lexaria’s
initial cannabidiol absorption study in 2016, rendered positive topline results.
Lexaria’s ingestible nicotine study using DehydraTECH delivered nicotine to the
bloodstream within 15 minutes, provided an increased gain of 148 percent of peak
nicotine to the bloodstream and produced 560 percent higher brain levels of
nicotine, where the nicotine’s effects are focused. Lower urine levels of
nicotine were also noted, signifying enhanced nicotine activity and
bioavailability, and lower quantities of key liver metabolites were found in the
bloodstream, suggesting bypass of first liver metabolism. Together, these
findings suggest a prolongation of nicotine effectiveness with the Lexaria
formulation, which may also be beneficial in controlling cravings over an
extended time period from a single edible nicotine dose.
All of this is good news for Lexaria and its proprietary technology. The
findings also prompt the question of whether the technology could be used to
help reduce unwanted side effects common to many other drugs. Ibuprofen, for
instance, can cause uncontrolled gastric bleeding and issues relating to liver
and kidney disease. While further analysis and testing is required, Lexaria
President John Docherty said that researchers are intrigued with the nicotine
study results.
“We are very pleased with these topline study findings demonstrating excellent
tolerability and substantially faster, more potent and bioavailable absorption
of nicotine in an ingestible format with our DehydraTECH technology than
controls,” Docherty said in the news release announcing the results. “This data
supports further investigation of the many possible benefits of our DehydraTECH
technology for nicotine delivery with potential both as a nicotine replacement
therapy as well as an alternative product format for regular tobacco users over
today’s inhaled options.”
Does Nicotine Have a Bad Rap?
Vanderbilt University Medical Center (VUMC) is one of 29 sites participating in
a national study funded by the National Institute on Aging to determine whether
a daily transdermal nicotine patch will have a positive effect on attention and
early memory impairment in older adults diagnosed with mild cognitive impairment
(MCI). More than eight million Americans are currently diagnosed with MCI, a
condition that affects memory or other thinking skills. Recent evidence shows
that adults with MCI are at a higher risk for subsequently developing
Alzheimer’s disease.
FDA Commissioner Dr. Scott Gottlieb has said that “the overwhelming amount of
the death and disease attributable to tobacco is caused by addiction to
cigarettes. Addiction causes long-term sustained use. But it’s exposure to the
harmful chemicals [from combustion] that causes disease (http://nnw.fm/r7Yo0).”
Paul Newhouse, M.D., director of the Center for Cognitive Medicine at VUMC and
national director of the study, said that nicotine, a natural plant alkaloid, is
a fascinating drug with interesting properties. “People think of it as a
potentially noxious substance, but it’s a plant-derived medication just like a
lot of other medications,” Newhouse stated in an article published by Vanderbilt
University (http://nnw.fm/lZf5f).
Global Goals
The worldwide smoking cessation and nicotine de-addiction market is expected to
reach over US$21.8 billion by 2024, according to a report by Grand View
Research, Inc. (http://nnw.fm/zpF9t). The increasing desire to quit smoking and
the numerous health complications associated with smoking serve as strong
incentives for companies to introduce novel smoking cessation products, the
report states.
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP) plans to partner, not
compete, with tobacco companies that are also seeking new ways to reduce the
known hazards of smoking and comply with upcoming Food and Drug Administration
regulations. Lexaria has entered into third-party licensing agreements within
the cannabis industry, and it seeks to do the same within the tobacco industry.
And according to Euromonitor International and British American Tobacco, p.l.c.,
the global nictotine/tobacco market is US$980 billion per year: Lexaria’s
technology could also find great applicability as a potential long-term
alternative form of nicotine delivery to replace combusted forms. The world’s
top tobacco companies may be in trouble: Phillip Morris lost $20 billion in
market cap in a single day on April 19 after revenue results for one of its
noncombusted delivery products disappointed the market. Frankly, the tobacco
industry may be looking for new technology like Lexaria offers to preserve their
massive businesses.
Lexaria’s DehydraTECH provides a complementary layer suitable for a versatile
range of commercial applications, allowing for a potentially healthier
alternative to smoking or vaping practices for both cannabis and nicotine users.
With more than 35 patents pending in over 40 countries, Lexaria is the only
company in the world with a patent in the United States and Australia for the
improved (oral or ingestible) delivery of all nonpsychoactive cannabinoids. And
Lexaria’s technology is already patent granted in the US for delivery of
nicotine.
Making a Difference
Lexaria’s pointedly focused research is devoted to understanding the human
endocannabinoid system and how it can function at a higher level through the
efficient and healthy ingestion of cannabinoids, but its research efforts are
compatible with a wide range of consumer-related compounds. Bioavailability
matters a lot, as all biotechnology companies are aware. Higher bioavailability
is often associated with lower overall doses of certain molecules, which can be
related to reduced stress on the liver and other organs. In addition, it may
also generate cost savings for consumers.
Working solely in the field of plant-derived cannabinoid therapeutics, GW
Pharmaceuticals Plc (NASDAQ: GWPH) has developed the world’s first prescription
medicine derived from the cannabis plant. Sativex® is now approved in numerous
countries outside of the United States for the treatment of spasticity due to
multiple sclerosis. The company’s deep pipeline of additional clinical stage
cannabinoid product candidates is focused on neurological conditions. Lead
product candidates include Epidiolex®, which is initially designed to treat rare
and severe early-onset, drug resistant epilepsy syndromes.
CV Sciences, Inc. (OTCQB: CVSI) operates in two distinct divisions —
pharmaceuticals and consumer products — with both utilizing cannabidiol
products. CV Sciences’ Pharmaceutical Division is pursuing FDA approval for the
development of synthetically formulated cannabidiol-based medicines. The
company’s consumer division already distributes botanical-based cannabidiol
products nationally in health food stores, in the offices of health care
providers and online.
22nd Century Group, Inc. (NYSE: XXII) is a plant biotechnology company whose
long-term focus is on reducing the harm caused by smoking. The company’s
proprietary genetic engineering technology and plant breeding expertise results
in tobacco plants that have up to 97 percent less nicotine than conventional
tobacco, as well as plants with relatively high nicotine levels. The
applications for this technology include a very low nicotine tobacco that can be
used in smoking cessation aid products and a tobacco with a low tar-to-nicotine
ratio for those who do not want to quit smoking but want to ingest less of the
known harmful byproducts of tobacco products.
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) is dedicated to the development and
commercialization of innovative transdermal pharmaceutically produced
cannabinoid treatments for rare and near-rare neuropsychiatric conditions in
patients with high, unmet medical needs. Zynerba’s ZYN002 CBD gel is the first
and only pharmaceutically produced CBD formulated as a patent-protected
permeation-enhanced transdermal gel. It is being studied in children and
adolescents with Fragile X syndrome and developmental and epileptic
encephalopathies, as well as in adult epilepsy patients with facial seizures.
Healthier Options
Cigarette smoking remains the leading cause of preventable disease and death in
the United States, according to the Centers for Disease Control (http://nnw.fm/aC6IZ).
The launch of improved and innovative nicotine replacement therapy products is
expected to make a significant impact on this multibillion-dollar market as more
people around the globe become increasingly aware of the health hazards tied to
smoking.
For more information on Lexaria, please visit
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP)
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that
provides (1) access to a network of wire services via NetworkWire to reach all
target markets, industries and demographics in the most effective manner
possible, (2) article and editorial syndication to 5,000+ news outlets (3),
enhanced press release services to ensure maximum impact, (4) social media
distribution via the Investor Brand Network (IBN) to nearly 2 million followers,
(5) a full array of corporate communications solutions, and (6) a total news
coverage solution with NNW Prime. As a multifaceted organization with an
extensive team of contributing journalists and writers, NNW is uniquely
positioned to best serve private and public companies that desire to reach a
wide audience of investors, consumers, journalists and the general public. By
cutting through the overload of information in today’s market, NNW brings its
clients unparalleled visibility, recognition and brand awareness. NNW is where
news, content and information converge. For more information, please visit
https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the NetworkNewsWire website
applicable to all content provided by NNW, wherever published or re-published:
http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set
forth above. References to any issuer other than the profiled issuer are
intended solely to identify industry participants and do not constitute an
endorsement of any issuer and do not constitute a comparison to the profiled
issuer. FN Media Group (FNM) is a third-party publisher and news dissemination
service provider, which disseminates electronic information through multiple
online media channels. FNM is NOT affiliated with NNW or any company mentioned
herein. The commentary, views and opinions expressed in this release by NNW are
solely those of NNW and are not shared by and do not reflect in any manner the
views or opinions of FNM. Readers of this Article and content agree that they
cannot and will not seek to hold liable NNW and FNM for any investment decisions
by their readers or subscribers. NNW and FNM and their respective affiliated
companies are a news dissemination and financial marketing solutions provider
and are NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy any
security.
The Article and content related to the profiled company represent the personal
and subjective views of the Author, and are subject to change at any time
without notice. The information provided in the Article and the content has been
obtained from sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all such
information. None of the Author, NNW, FNM, or any of their respective
affiliates, guarantee the accuracy or completeness of any such information. This
Article and content are not, and should not be regarded as investment advice or
as a recommendation regarding any particular security or course of action;
readers are strongly urged to speak with their own investment advisor and review
all of the profiled issuer's filings made with the Securities and Exchange
Commission before making any investment decisions and should understand the
risks associated with an investment in the profiled issuer's securities,
including, but not limited to, the complete loss of your investment.
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and NNW and FNM undertake no obligation to update
such statements.
NetworkNewsWire (NNW) is affiliated with the Investor Brand Network (IBN).
About IBN
Over the past 10+ years we have consistently introduced new network brands, each
specifically designed to fulfil the unique needs of our growing client base and
services. Today, we continue to expand our branded network of highly influential
properties, leveraging the knowledge and energy of specialized teams of experts
to serve our increasingly diversified list of clients.
Please feel free to visit the Investor Brand Network (IBN)
www.InvestorBrandNetwork.com
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Media Contact:
FN Media Group, LLC
NNW@FinancialNewsMedia.com
+1-(954)345-0611
News Source: NetworkNewsWire
Cannabis Biotech Booms
New York, NY – April 3, 2018 –
CannabisNewsWire.com News
Coverage: The tremendous growth of the licensed cannabis market has
naturally led to an increase in research in this area. A number of specialist
biotech companies have emerged, creating innovative cannabinoid applications.
Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed technology
to improve the palatability and speed of absorption of cannabinoid therapeutics,
leading to a range of licensed
products
and related patents. Plant biotechnology company 22nd Century Group, Inc. (NYSE:
XXII) is altering the level of active ingredients in both cannabis and tobacco,
allowing new strains to be grown for medical and other purposes. GW
Pharmaceuticals plc (NASDAQ: GWPH) has developed extensive expertise in
research, regulatory allowances and manufacturing, creating a pipeline of
products for illnesses including epilepsy and multiple sclerosis. INSYS
Therapeutics, Inc. (NASDAQ: INSY) is creating drugs for previously unmet patient
needs, researching novel systems to deliver active ingredients as effectively as
possible. Even rare illnesses are being addressed by this research boom, with
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) focusing on neurological disorders,
including fragile X syndrome and Tourette’s syndrome.
The Importance of Cannabis Biotech
As the cannabis market grows, biotechnology is taking an increasingly important
place in that market.
From a position of almost global illegality 20 years ago, cannabis is evolving
into a multibillion-dollar legal industry. Shifting social attitudes have led to
the legalization of licensed medical cannabis in more than half of the United
States and in many other countries around the world. A handful of countries are
also now moving to legalize the recreational use of cannabis, accelerating the
growth of the industry. Because of these changes, much of the public’s attention
has been on social and legal developments.
This focus ignores the groundbreaking work emerging from cannabis research and
design departments. Biotechnology has become a crucial part of the cannabis
market as researchers explore new applications for the plant’s active
ingredients and new ways of delivering drugs derived from them. This has led to
exciting efforts in tackling opioid addiction, helping brains age more healthily
and managing the symptoms of Parkinson’s disease, just to name a few. The
medical application of cannabis is becoming more sophisticated, and the cannabis
biotech sector is growing in both power and profitability.
Business-to-Business Biotech
Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has taken an important
place in this part of the market.
Lexaria is a research-driven company whose work focuses on improved drug
delivery systems. This expertise started with DehydraTECH™, a technology that
has been proven both in the laboratory and the market to improve the consumption
of beneficial compounds.
Many of these compounds are lipophilic, meaning they are fat soluble. They taste
and smell unpleasant, are poorly absorbed by the body, and are vulnerable to
being broken down by the stomach and metabolized away by the liver. This
leads to poor bioavailability, or how much of the compound the body can use.
Smoking, vaping and added chemicals have all been used to try to alleviate this,
but DehydraTECH offers a different solution. The lipophilic compound is combined
with fatty acids in a process that makes it nearly odorless and tasteless while
protecting it from hostile stomach conditions to increase both its speed of
delivery to appropriate biological systems and rate of absorption.
This technology can also be applied to vitamins, supplements, nicotine and
pharmaceuticals. And it is particularly applicable for both cannabis and
tobacco-derived drugs because it allows patients to benefit from the active
ingredients without having to smoke, thereby reducing harmful side effects from
smoking. By increasing the efficacy of drugs, the technology also reduces
quantities needed, cutting costs and minimizing drug-related side effects.
Lexaria has focused on licensing out its technology utilizing a business model
similar to that used by software companies. Through licensing agreements with
companies in Canada, the United States and beyond, Lexaria’s technology could
benefit patients around the world. Meanwhile, the company itself can stay
focused on biotechnology research without the burden of expensive commercial
operations.
Piling Up the Patents
The result is a company that has developed a significant volume of intellectual
property in its short history — and that volume continues to grow. Currently
Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has 15 patent
applications filed in the United States and over 30 pending in more than 40
countries, plus two patents granted for cannabinoid delivery in the United
States and one granted in Australia. With researchers continuing to refine the
DehydraTECH system, the patents keep piling up.
In March the company received a Notice of Allowance from the United States
Patent and Trademark Office relating to substances that improve the taste and
absorption of cannabinoids (http://cnw.fm/A14bT). This is expected to lead to
the granting of yet another U.S. patent soon to add more protected commercial
values for Lexaria’s partnered companies.
The company is also exploring the use of DehydraTECH in the absorption of drugs
through the skin. Lexaria has recently filed a new patent to improve the speed
and quantity of absorption for transdermal applications (http://cnw.fm/4sYzF). A
recent breakthrough in testing discovered that DehydraTECH can double the
transdermal absorption of cannabidiol compared with leading commercial
alternatives. This will allow the company to newly license its technology to
create improved patches, creams, cosmetics and more.
In addition, the company’s work has been enhanced through an R&D agreement with
the Canadian government’s National Research Council. This agreement is expected
to result in a better understanding of how Lexaria’s technology works, leading
to more agreements with other businesses.
It is ironic that this technology was developed for the cannabis industry but
has already received patent protection for many other commonly used drugs.
Anti-inflammatory drugs, vitamins and nicotine could all be deployed using
Lexaria’s disruptive technology. Supplements, pain relief and smoking-cessation
or smoking-alternative nicotine products are all possible as a result of
Lexaria’s research. To this end, the company recently commenced a study into
nicotine absorption (http://cnw.fm/DLo69). Who would have thought that cannabis
research might lead to broader biotechnology applications that could benefit
non-cannabis consumers?
Immediate Benefits
Cannabis is a fast-growing sector; moving quickly to develop and deploy new
technology is important. Every year sees new areas of the world opening up to
licensed cannabis use, as well as new products being commercialized to make the
most of this market. Companies are rushing to develop the products that will
fill this developing market.
The sooner these products can be patented, the sooner they can be brought to
market, and Lexaria may again have a distinct first-mover advantage in this
area. With patents filed and backdated to 2014 for a range of related
technologies in dozens of different jurisdictions, the company may soon be able
to commercialize its systems around the globe. Lexaria’s IP is steadily
increasing, covering more effective bio-delivery of medical cannabis,
recreational cannabis and over-the-counter pain remedies such as aspirin and
ibuprofen. Through licensing to partner companies, Lexaria may soon be using
this technology to drive value and prove the advantage of its systems worldwide.
The Broader Picture of Cannabis Biotech
Of course,
Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) isn’t the only company
applying biotechnology to cannabis in a search for new products. A wide range of
research is leading to a diverse range of innovations set to disrupt this
exciting sector.
Plant biotech company 22nd Century Group (NYSE: XXII) is focused on changing the
chemical composition of plant strains. Initially working on tobacco, the company
has developed plants that have both very low and very high levels of nicotine.
This broad range can be used to help smokers quit or reduce harm to those still
smoking. Through its Botanical Genetics subsidiary, 22nd Century Group is
turning its attention to controlling the level of active ingredients in
cannabis. This has potential not only to create more effective medicines but
also to support industrial hemp growth by removing active ingredients so that
the plant can more easily be farmed for fibers and food.
Based in the United States and the United Kingdom, GW Pharmaceuticals plc
(NASDAQ: GWPH) is a developer of cannabinoid-based medicines. Twenty years of
work have given the company extensive expertise in research, regulations and
manufacturing, allowing it to manage the whole pipeline, from research
inspiration to a complete product. Its medicines are used in tackling the
symptoms of epilepsy and multiple sclerosis, with more in the research pipeline.
Like Lexaria, INSYS Therapeutics (NASDAQ: INSY) is focused on producing new
cannabinoid medicines and delivery systems to make better use of the drugs. The
company is also studying how to use the newly unleashed potential of cannabis to
create drugs for previously unmet patient needs. New drugs developed by the
company’s researchers may help medical professionals support patients who
previously lacked effective treatment. Drugs in the pipeline include an oral
treatment for treating spasms in children.
Zynerba Pharmaceuticals (NASDAQ: ZYNE) is developing cannabis-based treatments
for rare and near-rare neurological disorders. The company is working on
transdermal drugs to help patients suffering from fragile X syndrome, certain
forms of epilepsy and Tourette’s syndrome.
Cannabis biotech efforts are unleashing a range of new treatments. As more is
discovered about the cannabis plant’s potential, treatments for a range of
previously hard-to-manage conditions are being found along with better options
for widespread illnesses. In providing innovative solutions and new products,
the sector is growing in sophistication and strength.
For more information on Lexaria, please visit
Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP).
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our
news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize
corporate news and information, (3) enhanced press release services, (4) social
media distribution and optimization services, and (5) a full array of corporate
communication solutions. As a multifaceted financial news and content
distribution company with an extensive team of contributing journalists and
writers, CNW is uniquely positioned to best serve private and public companies
that desire to reach a wide audience of investors, consumers, journalists and
the general public. CNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting through the
overload of information in today’s market, CNW brings its clients unparalleled
visibility, recognition and brand awareness. CNW is where news, content and
information converge.
Receive Text Alerts from CannabisNewsWire: Text "Cannabis" to 21000
For more information please visit https://www.CannabisNewsWire.com and or
https://CannabisNewsWire.News
Please see full terms of use and disclaimers on the CannabisNewsWire website
applicable to all content provided by CNW, wherever published or re-published:
http://CNW.fm/Disclaimer
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set
forth above. References to any issuer other than the profiled issuer are
intended solely to identify industry participants and do not constitute an
endorsement of any issuer and do not constitute a comparison to the profiled
issuer. FN Media Group (FNM) is a third-party publisher and news dissemination
service provider, which disseminates electronic information through multiple
online media channels. FNM is NOT affiliated with CNW or any company mentioned
herein. The commentary, views and opinions expressed in this release by CNW are
solely those of CNW and are not shared by and do not reflect in any manner the
views or opinions of FNM. Readers of this Article and content agree that they
cannot and will not seek to hold liable CNW and FNM for any investment decisions
by their readers or subscribers. CNW and FNM and their respective affiliated
companies are a news dissemination and financial marketing solutions provider
and are NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy any
security.
The Article and content related to the profiled company represent the personal
and subjective views of the Author, and are subject to change at any time
without notice. The information provided in the Article and the content has been
obtained from sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all such
information. None of the Author, CNW, FNM, or any of their respective
affiliates, guarantee the accuracy or completeness of any such information. This
Article and content are not, and should not be regarded as investment advice or
as a recommendation regarding any particular security or course of action;
readers are strongly urged to speak with their own investment advisor and review
all of the profiled issuer's filings made with the Securities and Exchange
Commission before making any investment decisions and should understand the
risks associated with an investment in the profiled issuer's securities,
including, but not limited to, the complete loss of your investment.
CNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and CNW and FNM undertake no obligation to update
such statements.
CannabisNewsWire (CNW) & NetworkNewsWire (NNW) are proud to be affiliated
partners of the Investor Brand Network (IBN)
About IBN
Over the past 10+ years we have consistently introduced new network brands, each
specifically designed to fulfil the unique needs of our growing client base and
services. Today, we continue to expand our branded network of highly influential
properties, leveraging the knowledge and energy of specialized teams of experts
to serve our increasingly diversified list of clients.
Please feel free to visit the Investor Brand Network (IBN) http://www.InvestorBrandNetwork.com
Corporate Communications Contact:
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
Media Contact:
FN Media Group, LLC
NNW@FinancialNewsMedia.com
+1-(954)345-0611
News Source: CannabisNewsWire
Smokers Light Up Less, Alternative Nicotine Delivery Technologies Take Center
Stage
New York, NY – March 6, 2018 –
NetworkNewsWire.com News
Coverage: American smokers are stubbing out their cigarettes. Data
from the Centers for Disease Control and Prevention (CDC) show that the
proportion of the adult American population that has smoked at least 100
cigarettes during their lifetimes stood at 15.5 percent in 2016, down from 20.9
percent
in 2005 (http://nnw.fm/J6dQp). Of course, quitting smoking does not always mean
saying no to nicotine. The stimulant, credited with some health benefits, is
highly addictive. As a result, alternative delivery biotechnologies for nicotine
have become a recent R&D focus for cigarette manufacturers and other companies,
including
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP), Altria Group, Inc.
(NYSE: MO), British American Tobacco (LSE: BATS), Imperial Brands, (LSE: IMB)
(OTC: IMBBY) and Philip Morris International, Inc. (NYSE: PM). With close to 38
million American smokers still puffing away, and nearly 1 billion worldwide,
these companies are developing safer products and delivery technologies, which
may wean smokers away from a habit estimated to kill about 480,000 (1 in 5)
adult Americans every year.
In the 20th Century, the average American was smoking 4,345 manufactured
cigarettes per year (http://nnw.fm/k7n5A). In the early 1960s, the Surgeon
General of the United States published a damning report that linked smoking to
lung cancer, emphysema and heart disease, and since then the percentage of
American adults who smoke has declined in every year the CDC has surveyed.
Around the time of the Surgeon General’s warning in 1963, 42.4 percent of
American adults smoked; 50 years later, in 2013, that rate had fallen to 21.6
percent. In 2016, it dipped even further to 15.5 percent (http://nnw.fm/Mo3wa).
Recognizing this significant downturn, paired with the fact that regardless of
health risks a population of consumers will continue nicotine use, biotech
innovators and even big tobacco companies are looking for ways to reduce the
hazards of smoking.
The Case for Smoking Alternatives
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP) is gaining prominence
for its proprietary delivery technology capable of changing the way active
pharmaceutical ingredients (“APIs”) such as cannabinoids and nicotine enter the
body. The company’s DehydraTECH™ technology enables delivery of lipophilic
active agents within foods, beverages, capsules and other ingestible formats,
thus improving the performance of beneficial ingestible products across four
categories: taste, smell, speed of action, and bioabsorption and
bioavailability. DehyraTECH has already been proven effective in cannabinoid
delivery and is currently undergoing testing for nicotine delivery in lab
animals.
When it comes to smoking, this is of considerable importance for two reasons.
First, in 2016 a Royal College of Physicians (RCP) report concluded that
“nicotine alone in the doses used by smokers represents little if any hazard to
the user” – rather, it is the combination of more than 4,000 chemicals released
from the combustion of tobacco that is damaging. Complementary to this finding
is research by the BMJ, which shows that there is no safe level of smoking and
that “only complete cessation is protective and should be emphasized by all
prevention measures and policies … any exposure to cigarette smoke is too much.”
Secondly, Lexaria’s technology addresses a vital concern smoking poses to the
body: human lungs were not designed to become pathways for drug absorption;
their sole purpose is to deliver oxygen to the blood. Nature did, however,
design an ingenious system for drug and nutrient absorption, and that method is
ingestible food and drink.
Lexaria’s technology is custom-designed to work with the human gastro intestinal
(GI) system to deliver APIs more effectively (DehydraTECH can deliver payload
molecules to the bloodstream in as little as 10 to 15 minutes, as opposed to 60
to 90 minutes for current methods), but still respects the body’s inherent
internal safety mechanisms.
Delivering minute proportions of nicotine through edible food formats like
coffee or breath mints has never been successfully achieved in the past, because
when detected by the GI system, nicotine is generally flushed from the
intestines through cramping and GI distress.
Lexaria’s DehyraTECH technology, however, acts as a trojan horse, demonstrating
potential to deliver nicotine through the GI with sharply lowered side effects.
Patented Technology is Rooted in Cannabinoids, Includes Nicotine Coverage
At present,
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP) is the only company in
the world that has been awarded patents for the improved (oral or ingestible,
including pills) delivery of all cannabinoids both psychoactive and non. These
patents have been awarded in the United States and Australia and are pending in
40 more countries. This puts the company in the unusually advantageous position
of owning proprietary technology that can deliver a vast range of cannabinoid-based
drugs.
The company recently received a new patent award in the U.S. that also protects
its delivery system for use with nicotine, potentially offering the biggest
disruption to nicotine delivery since the invention of the cigarette.
“Lexaria has now locked-up the IP for its next-generation drug delivery system”
Lexaria CEO Chris Bunka explained in the press release (http://nnw.fm/Q8JxJ).
“This ground-breaking, patented IP builds a foundation for new business
opportunities in 2018 including what could be the world’s first nicotine edibles
for the smokeless tobacco industry, or improved new products for NSAID-derived
pain management, as well as in the rapidly growing cannabis market.”
Licensing Model in Action
Lexaria’s DehydraTECH system is being utilized in a number of consumer products
developed by the company under three distinct brands: ViPova™, Lexaria Energy
and TurboCBD™. In recent months, Lexaria has executed several key agreements
that demonstrate the versatility of its technology and serve as examples of the
company’s out-licensing model.
Most recently, Lexaria entered into a five-year licensing agreement with Biolog,
Inc., in which Biolog (a Utah company, not to be confused with a California cell
phenotyping company of the same name) will use DehydraTECHTM to empower a unique
set of next-generation food and beverage cannabis infusion products to be sold
in the United States (http://nnw.fm/8FvlH).
In January 2018,
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP) also announced a
licensing agreement with Cannfections Group, Inc. Per the agreement, Lexaria
will provide its DehydraTECH technology to enhance the performance of
Cannfections’ cannabis-infused chocolates and candies to be developed and sold
in Canada and internationally. The founders of Cannfections currently
manufacture chocolate retail products for several leading international and
domestic chocolate brands (http://nnw.fm/Ovvy7).
Tobacco Industry Potential
Rather than being a competitor to tobacco and cannabis companies, Lexaria aims
to out-license its technology to third-party partners such as major cigarette
manufacturers. Lexaria is expected to conduct its first in-vivo nicotine
absorption tests in March and results are expected shortly thereafter. If
positive, the industry could have its first data supporting a viable delivery
technique for edible forms of nicotine. Tests are being conducted at a highly
regarded, third-party laboratory.
Two giants in the industry, Altria Group, Inc. (NYSE: MO) and Philip Morris
(NYSE: PM), are collaborating on the production and distribution of a gadget
that they claim will reduce the risk of tobacco-related ailments for smokers who
eschew cigarettes in favor of it. However, the partnership appears to be sailing
through rough waters. A Food and Drug Administration (FDA) panel concluded
almost unanimously (one abstention in the 8-0 vote) that Philip Morris had not
shown that its heat-not-burn device reduces the risk of smoking-related
ailments. The panel did find, however, that switching to the device, known as
the iQos, reduces exposure to harmful chemicals (http://nnw.fm/xsW9F).
Meanwhile, British American Tobacco (LSE: BATS.L) emphasizes the economic value
of tobacco in general, but has also invested more than $1 billion into the
development of Next Generation Products (“NGPs”) such as e-cigarettes and
tobacco-heating products.
Without abandoning its core focus on cigarettes and other tobacco products,
Imperial Brands, (LSE: IMB.L) (OTCQX: IMBBY) is also exploring the potential of
NGPs to offer smokers an alternative to combustible tobacco. “ … NGPs offer us
considerable growth opportunities. We are significantly stepping up our level of
NGP activity in 2018 and beyond, expanding our portfolio with new product
launches in new and existing markets,” the company states on its website.
With big tobacco on board to cater to consumer trends, Lexaria occupies an
interesting position in the marketplace as it continues to advance its
alternative delivery system for potential out-licensing to companies like
Altria, Philip Morris, British American Tobacco, Imperial Brands and others. The
global tobacco industry is almost unimaginably large and orders of magnitude
larger than cannabis. If proven effective, Lexaria’s technology could have the
most practical and healthful application to the world’s 1 billion smokers than
anything that has come before.
For more information on Lexaria, visit
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP)
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that
provides (1) access to a network of wire services via NetworkWire to reach all
target markets, industries and demographics in the most effective manner
possible, (2) article and editorial syndication to 5,000+ news outlets (3),
enhanced press release services to ensure maximum impact, (4) social media
distribution via the Investor Brand Network (IBN) to nearly 2 million followers,
(5) a full array of corporate communications solutions, and (6) a total news
coverage solution with NNW Prime. As a multifaceted organization with an
extensive team of contributing journalists and writers, NNW is uniquely
positioned to best serve private and public companies that desire to reach a
wide audience of investors, consumers, journalists and the general public. By
cutting through the overload of information in today’s market, NNW brings its
clients unparalleled visibility, recognition and brand awareness. NNW is where
news, content and information converge. For more information, please visit
https://www.NetworkNewsWire.com.
Please see full terms of use and disclaimers on the NetworkNewsWire website
applicable to all content provided by NNW, wherever published or re-published:
http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set
forth above. References to any issuer other than the profiled issuer are
intended solely to identify industry participants and do not constitute an
endorsement of any issuer and do not constitute a comparison to the profiled
issuer. FN Media Group (FNM) is a third-party publisher and news dissemination
service provider, which disseminates electronic information through multiple
online media channels. FNM is NOT affiliated with NNW or any company mentioned
herein. The commentary, views and opinions expressed in this release by NNW are
solely those of NNW and are not shared by and do not reflect in any manner the
views or opinions of FNM. Readers of this Article and content agree that they
cannot and will not seek to hold liable NNW and FNM for any investment decisions
by their readers or subscribers. NNW and FNM and their respective affiliated
companies are a news dissemination and financial marketing solutions provider
and are NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy any
security.
The Article and content related to the profiled company represent the personal
and subjective views of the Author, and are subject to change at any time
without notice. The information provided in the Article and the content has been
obtained from sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all such
information. None of the Author, NNW, FNM, or any of their respective
affiliates, guarantee the accuracy or completeness of any such information. This
Article and content are not, and should not be regarded as investment advice or
as a recommendation regarding any particular security or course of action;
readers are strongly urged to speak with their own investment advisor and review
all of the profiled issuer's filings made with the Securities and Exchange
Commission before making any investment decisions and should understand the
risks associated with an investment in the profiled issuer's securities,
including, but not limited to, the complete loss of your investment.
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and NNW and FNM undertake no obligation to update
such statements.
NetworkNewsWire (NNW) is affiliated with the Investor Brand Network (IBN).
About IBN
Over the past 10+ years we have consistently introduced new network brands, each
specifically designed to fulfil the unique needs of our growing client base and
services. Today, we continue to expand our branded network of highly influential
properties, leveraging the knowledge and energy of specialized teams of experts
to serve our increasingly diversified list of clients.
Please feel free to visit the Investor Brand Network (IBN)
www.InvestorBrandNetwork.com
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Media Contact:
FN Media Group, LLC
NNW@FinancialNewsMedia.com
+1-(954)345-0611
News Source: NetworkNewsWire
Cannabis Deals Cross the Billion-Dollar Mark in Canada
New York, NY – February 6, 2018 –
NetworkNewsWire.com News
Coverage: With the expected legalization of recreational cannabis use
in Canada just months away, the Canadian cannabis industry is experiencing a
frenzied flow of
capital
that is only likely to accelerate. While this capital rush won’t affect every
company in the space, the overriding sentiment supports global aspirations and
trickle-down opportunity for innovators like
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP). This unprecedented
cash flow is already fueling the construction of the largest grow facilities the
world has ever seen, as well as increasingly hectic merger and acquisition
strategies undertaken by companies like MedReleaf (OTC: MEDFF) (TSX: LEAF),
Aurora Cannabis, Inc. (OTC: ACBFF) (TSX: ACB), Cronos Group, Inc. (OTC: PRMCF) (TSX-V:
MJN) and Organigram Holdings, Inc. (OTC: OGRMF) (TSX-V: OGI).
Reuters has reported that the value of cannabis deals this year has already
reached $1.2 billion, more than double the total for 2017, which was itself a
record (http://nnw.fm/14nLi). For these pioneers of pot, halcyon days lie ahead
in 2018. For perspective, contrast Canada’s revenue outlook with the U.S.-based
Arcview Group, which bills itself as the largest cannabis-focused investment
network in the world. It has taken Arcview members several years to raise a
total of US$150 million, which is no small accomplishment in a country where
federal cannabis regulations can still put you in prison, but not remotely
competitive against the billions being raised north of the 49th parallel.
It may be inevitable that some portion of the billions of Canadian cannabis
money find their way into either developing, licensing, or buying the technology
necessary to dominate the rapidly developing global legal cannabis market, and
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP) has positioned itself
squarely in the midst of this trend.
Lexaria’s Golden Nugget: Drug Delivery Technology
Innovators in the field of drug delivery engineer technologies to improve the
targeting of therapeutic agents and their controlled release. In general, drug
therapies have vastly enhanced Hippocratic practices but many come with
pernicious side effects, since active agents very often cannot discriminate
between healthy and unhealthy cells. Some others, although rather more benign,
require large dosages or prolonged treatment since, with current delivery
methods, much of the active agent is simply not absorbed by the body and goes to
waste.
However, Lexaria has developed an oral digestion technology, DehydraTECH™, which
improves the absorption rates of nicotine, non-steroid anti-inflammatory drugs (NSAIDs),
vitamins and cannabinoids, by as much as five to 10 times. The significance of
this edible technology is that this improved absorption may translate into lower
dosages and shorter
treatment regimens.
DehydraTECH also improves delivery times, delivering payload molecules to the
bloodstream in 15-25 minutes, as opposed to 60-90 minutes for current methods.
The new patented, disruptive drug delivery platform changes the way Active
Pharmaceutical Ingredients (APIs) enter the body orally. The technology
eliminates the need to add high concentrations of sweeteners, since it masks
unwanted tastes. But, more importantly, it avoids first-pass liver metabolism,
which mitigates side effects and improves the bioavailability of its client
drug.
Ingestion of a medication, typically, follows a prescribed path. After the
digestive system absorbs the ingredients, they are moved to the hepatic portal
system en route to the liver. The liver, which among other things converts foods
into the nutrients that can be used by the body, dutifully embarks on its
routine of metamorphosis. Unfortunately, many therapeutic agents are neutralized
in the process, which is why those that bypass the liver, using DehydraTECH for
instance, tend to be more effective.
Edible Integration
DehydraTECH has already proven its mettle as Lexaria has deployed the innovative
delivery platform to its product line. This consists of distinct brands: ViPova
and TurboCBD. ViPova is a delicious Chinese black tea from the province of
Yunnan, made from hemp oil infused within dried evaporated non-fat milk.
Introduced in January 2015, the tea is available in a variety of flavors. In
addition, there is Lexaria’s TurboCBD, a brand of technologically enhanced, high
absorption hemp oil capsules that came to market in March 2017. TurboCBD’s
cannabinoid content is fortified with high-quality American ginseng and ginkgo
biloba to support enhanced focus and memory while reducing stress and fatigue.
Lexaria’s Engine of Growth is its Drug Delivery Platform
Despite the refreshing range of products, what’s under the hood matters more.
Since the DehydraTECH technology can be used to improve the delivery of a wide
range of substances, including ibuprofen, nicotine, fat-soluble vitamins, THC
and CBD, this puts Lexaria in the enviable position of being a natural partner
to cannabinoid biotech companies as their star rises, situated as an enabler
rather than a competitor. Moreover, at present, Lexaria is the only company in
the world that has been awarded a patent for the improved delivery (oral or
ingestible, including capsules and pills) of all non-psychoactive cannabinoids.
Patents have been awarded in the United States and Australia and are pending in
40 more countries, as well as transnationally under the Patent Cooperation
Treaty, as Lexaria’s patent portfolio grows. The company has filed 19 patent
applications that include both method and composition of matter claims. The
patents issued in the United States and Australia include “Food and Beverage
Compositions infused with Lipophilic Active Agents and Methods of Use thereof.”
This puts the company in the unusually advantageous position of owning
proprietary technology that can deliver a vast range of non-psychoactive
cannabinoid-based drugs. Lexaria has already had discussions with major
pharmaceutical and other Fortune 500 companies regarding its technology. The
smallest deal with any one of these could increase revenues by over $1 million;
the largest by much, much more, according to CEO Chris Bunka in a recent
interview (http://nnw.fm/jY9gG). Moreover, Lexaria’s licensing model will
generate revenues at very little cost, leaving 90 to 100 percent of revenues as
profit.
Key Developments
On Jan. 25, 2018,
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP) announced it had
entered one such technology licensing agreement with Cannfections Group Inc.,
which produces cannabis-infused chocolates and candies (http://nnw.fm/qLBl3).
Cannfections Group has been newly established by one of Canada’s leading
chocolate companies, which has over 85 years of experience in producing high
quality chocolate and confectionary products. The parent company currently
manufactures chocolate retail products for several leading international and
domestic chocolate brands.
“By licensing our technology to Cannfections, Lexaria can now offer its
commercial clients the expertise of one of Canada’s oldest and most established
chocolatiers utilizing next-generation DehydraTECHTM technology,” Bunka stated
in the press release. “This is a long term strategic relationship meant to offer
technology, value and expertise to Licensed Producers wanting to offer the
highest quality chocolate edibles available in Canada once permitted under
Health Canada regulations.”
Canadian Cannabis Wheeling & Dealing
Cannabis market leaders are providing their investors with unheralded liquidity
while other leaders are hot on the investment and acquisition path. And in
recent weeks and months, governments in Australia, Italy, the Netherlands,
Germany and elsewhere have begun to open their markets to cannabis imports and
exports for the first time in history, allowing for the beginnings of a global
market in cannabis trade.
MedReleaf’s (OTC: MEDFF) (TSX: LEAF) recent Initial Public Offering (IPO) of
approximately $75 million is thus far the largest marijuana company IPO in North
America. MedReleaf, the first and only ISO 9001 certified cannabis producer in
North America, was founded just four years ago and is one of less than four
dozen licensed producers and retailers of medical cannabis products in Canada.
Its focus is on the supply of dried cannabis, cannabis oils, and cannabis oil
capsules to qualified medical patients in Canada but it also sells various
accessories, such as vaporizers and grinders. Earlier this month, the company
released details of further possible capital inflows. It announced an agreement
with Canaccord Genuity Corp. and GMP Securities L.P (http://nnw.fm/g1GgG) under
which the two underwriters will purchase the company’s common stock in a deal
valued at C$100.7 million (US$85.8).
Some of that cannabis cash is also likely to pay for Aurora Cannabis’ (OTCQX:
ACBFF) (TSX: ACB) 800,000-square-foot state-of-the-art Aurora Sky project and
help Canada’s No. 2 marijuana producer take over smaller rival CanniMed
Therapeutics Inc for C$1.1 billion (US$852 million). Aurora had originally made
a hostile bid capped at C$24 (US$20.45) per share for CanniMed, but this new
offer was priced at C$43 (US$36.64). The deal marked the world’s biggest
marijuana M&A transaction to date.
Meanwhile, the Cronos Group, Inc. (OTC: PRMCF) (TSX-V: MJN) is doing deals too.
In January 2018, the company announced the closing of its C$46 million bought
deal public offering (http://nnw.fm/Qdc3S), the proceeds of which the company
has allocated toward expanding production capacity, research and development
initiatives, and for general working capital purpose. Cronos Group is a
geographically diversified and vertically integrated cannabis company that
operates two wholly owned licensed producers (LPs) regulated under Health
Canada’s Access to Cannabis for Medical Purposes Regulations (the ACMPR) and
holds a portfolio of minority investments in other licensed producers. The
company’s flagship LPs, Peace Naturals Project Inc. (Ontario) and Original BC
Ltd. (British Columbia), are collectively situated on over 125 acres of
agricultural, licensed land. Peace Naturals Project Inc. recently obtained a
Dealer’s License pursuant to the Controlled Drugs and Substances Act under
Health Canada. This enables the Cronos Group, through Peace, to export medical
cannabis extracts, including concentrated oil and resin products,
internationally.
Organigram Holdings (OTCQB: OGRMF) (TSX-V: OGI) is also cashing in on investor
optimism. The company made public its agreement with Eight Capital under which
Eight Capital and others will purchase 100,000 convertible debentures at a price
of $1,000 per debenture for a total of $100 million (http://nnw.fm/39euQ). The
company said it intends to use part of the net proceeds of that offering to
expand its domestic and overseas market presence.
Anticipated Supply Shortfall
As legalization looms in Canada, investors are opening their checkbooks to a
wide range of cannabis companies. With legalization, demand for cannabis is
expected to surge. There are indications that, at present, a supply shortfall
could occur. In the short term, it looks like a seller’s market and the volume
of funds flowing into the industry is clear evidence of that.
For more information on Lexaria, visit
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our
news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize
corporate news and information, (3) enhanced press release services from
NetworkWire, (4) social media distribution and optimization services, and (5) a
full array of corporate communication solutions. As a multifaceted financial
news and content distribution company with an extensive team of contributing
journalists and writers, NNW is uniquely positioned to best serve private and
public companies that desire to reach a wide audience of investors, consumers,
journalists and the general public. NNW has an ever-growing distribution network
of more than 5,000 key syndication outlets across the country. By cutting
through the overload of information in today’s market, NNW brings its clients
unparalleled visibility, recognition and brand awareness. NNW is where news,
content and information converge. For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website
applicable to all content provided by NNW, wherever published or re-published:
http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set
forth above. References to any issuer other than the profiled issuer are
intended solely to identify industry participants and do not constitute an
endorsement of any issuer and do not constitute a comparison to the profiled
issuer. The commentary, views and opinions expressed in this release by NNW are
solely those of NNW. Readers of this Article and content agree that they cannot
and will not seek to hold liable NNW for any investment decisions by their
readers or subscribers. NNW is a news dissemination and financial marketing
solutions provider and are NOT registered broker-dealers/analysts/investment
advisers, hold no investment licenses and may NOT sell, offer to sell or offer
to buy any security.
The Article and content related to the profiled company represent the personal
and subjective views of the Author, and are subject to change at any time
without notice. The information provided in the Article and the content has been
obtained from sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all such
information. None of the Author, NNW, or any of their respective affiliates,
guarantee the accuracy or completeness of any such information. This Article and
content are not, and should not be regarded as investment advice or as a
recommendation regarding any particular security or course of action; readers
are strongly urged to speak with their own investment advisor and review all of
the profiled issuer’s filings made with the Securities and Exchange Commission
before making any investment decisions and should understand the risks
associated with an investment in the profiled issuer’s securities, including,
but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words such as “may”,
“future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”,
“draft”, “eventually” or “projected”. You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company’s annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and NNW undertakes no obligation to update such
statements.
NetworkNewsWire (NNW) is affiliated with the Investor Brand Network (IBN).
About IBN
Over the past 10+ years we have consistently introduced new network brands, each
specifically designed to fulfil the unique needs of our growing client base and
services. Today, we continue to expand our branded network of highly influential
properties, leveraging the knowledge and energy of specialized teams of experts
to serve our increasingly diversified list of clients.
Please feel free to visit the Investor Brand Network (IBN)
www.InvestorBrandNetwork.com
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Media Contact:
FN Media Group, LLC
NNW@FinancialNewsMedia.com
+1-(954)345-0611
News Source: NetworkNewsWire
Intriguing Research into Pathways to Limit Nicotine, Quit Cigarette Use
New York, NY – January 9, 2018 –
NetworkNewsWire.com News
Coverage: It’s no secret that cigarettes, a product whose toxins and
carcinogens have shown time and again to cause illness and a long list of
cancers, are addictive. Finding a way to stop smoking is an individual battle,
although there is hope that new products are on the horizon that may help
millions
of people win the fight. Several significant research and development projects
being undertaken by such innovators such as
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP) a company with
proprietary technology capable of changing the way active pharmaceutical
ingredients (“APIs”) such as nicotine enter the body. Even leading tobacco
brands like British American Tobacco p.l.c. (NYSE: BTI), Philip Morris
International (NYSE: PM), Altria Group Inc. (NYSE: MO) and Universal Corporation
(NYSE: UVV) are showing interest in contributing to the shift toward
nicotine-infused products and away from combustible cigarettes.
What, No Smoke?
That’s the goal, isn’t it? Products on the market today meant to help smokers
“kick the habit” are behind the counter of nearly every store that carries
dozens of cigarette brands. The U.S. Food and Drug Administration has approved
several forms of nicotine replacement therapy such as gum, transdermal patches,
sprays, inhalers or lozenges, and all are meant to help relieve some of the
physical withdrawal symptoms when a person tries to quit smoking (http://nnw.fm/2Nd9L).
Interestingly, the legal age for tobacco products and inhalant delivery system
such as e-cigarettes in Oregon was just raised from 18 to 21, effective January
1, 2018. That legislation puts Oregon in company with California, Hawaii, Maine
and New Jersey as the only states with such a legal limit (http://nnw.fm/d12X2).
The goal, according to state officials, is to stop young people from first
picking up a cigarette and avoid joining the millions of people who die each
year because of tobacco use.
Promising Research
Research teams at
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP), based in Kelowna,
British Columbia, Canada, have developed a new, disruptive drug delivery
platform called “DehydraTECH™ that changes the way APIs enter the body via oral
consumption. Lexaria’s patented delivery method could give the estimated 69
percent of U.S. adult smokers who say they want to quit a new way to do just
that. Utilizing Lexaria’s DehydraTECH™ technology to formulate edible products
containing nicotine and/or its analogues for this purpose offers unique
advantages to the consumer. The company’s newly issued U.S. patent award covers
the use of DehydraTECH™ technology as a broad delivery platform for a broad
range of APIs, including all cannabinoids, fat soluble vitamins, non-steroidal
anti-inflammatory pain medications (“NSAIDs”), and nicotine (http://nnw.fm/Do3iO).
“This wide-ranging patent allowance from the U.S. Patent and Trademark Office
exceeds our expectations” Lexaria Bioscience Chief Executive Officer Chris Bunka
stated in a press release (http://nnw.fm/4NAWd). “This vastly expanded
intellectual property protection will enable us to aggressively pursue new
business opportunities in 2018 such as what could be the world’s first nicotine
edibles for the smokeless tobacco industry, or enhanced products for NSAID-derived
pain management, as well as in the rapidly growing cannabis market.”
Advanced Delivery Method
Lexaria is accelerating its research focus on nicotine following its patent
grant and is preparing formulations of edible forms of nicotine using the
DehydraTECH™ technology. These formulations are currently completing quality
control testing prior to in vivo absorption and tolerability testing. A
third-party laboratory is expected to perform the first nicotine edible tests in
February 2018. Imagine an edible nicotine-infused product that: masks unwanted
tastes, eliminating the need for sugar-filled edibles; reduces the time of onset
with effects felt within 15-20 minutes instead of up to an hour or more; avoids
first-pass liver metabolism, which means fewer side effects; and increases
bio-absorption by five to 10 times which equates to an inhaled delivery method -
all while helping you quit smoking cigarettes.
Spotlight on Innovation
The FDA’s recent proposal to reduce nicotine levels in cigarettes to
non-addictive levels bodes well for companies like Lexaria whose patented
technology clearly supports the effort. Almost 90 percent of adult smokers
started smoking before the age of 18 and nearly 2,500 youth smoke their first
cigarette every day in the U.S., and the FDA’s comprehensive plan for tobacco
and nicotine regulation will serve as a multiyear roadmap to better protect
children and significantly reduce tobacco-related disease and death (http://nnw.fm/2SUkk).
Lowering nicotine levels could decrease the likelihood that future generations
become addicted to cigarettes and allow more currently addicted smokers to quit.
Market Implications
The company’s proprietary platform allows for the infusion of nicotine molecules
within a wide range of edible food ingredients or typical capsule formats,
effectively opening the door for the creation of a new product category
targeting the high-demand smoking cessation market (http://nnw.fm/vmNg7). While
this research is in its early stages, the market implications of maximizing Lexaria’s patented molecular delivery method in such areas as nicotine delivery,
non-steroidal anti-inflammatories (NSAIDs) and vitamins – all multibillion
dollar industries – is significant. According to a 2016 report by Grand View
Research, Inc., the global smoking cessation and nicotine de-addiction market is
expected to reach over $21.8 billion by 2024. As Grand View reports, “The launch
of… improved and innovative nicotine replacement therapy products is to serve as
a high impact rendering driver for the growth of the smoking cessation and
nicotine de-addiction market (http://nnw.fm/Ytnr1)”
Big Tobacco’s Take
The FDA’s mandate is even being touted by big tobacco companies whose fortunes
once solely rested on its combustible offerings. Smoke-free options are rapidly
becoming popular as the National Institute on Drug Abuse reports they often are
chosen by those wishing to lower nicotine cravings in their quest to stop
smoking cigarettes (http://nnw.fm/bM5vN). The FDA’s directive to lower nicotine
in cigarettes to non-addictive or less addictive levels is driving much of the
industry’s research and development drive. With more tobacco companies
acknowledging the hazards of smoking and changing their approach to nicotine
consumption,
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP) could have
incredible potential as a solution provider with its advanced delivery system.
British American Tobacco p.l.c. (NYSE: BTI), a global tobacco and nicotine
products company, sells its products in more than 200 markets worldwide. The
company’s push to develop “Next Generation Products,” such as e-cigarettes and
tobacco-heating products comes with a reminder that although these products are
not entirely without risk, they are considered to be significantly less than
smoking combustible cigarettes (http://nnw.fm/ss8Nv).
Philip Morris International (NYSE: PM), one of the three largest tobacco
companies in the world, trumpets its intention to design a “smoke-free future”
right on the front page of the company website, asking readers “How long will
PMI be in the cigarette business?” (http://nnw.fm/7Mih6). The company states it
is developing and testing products that deliver nicotine without the harmful
smoke of cigarettes. In fact, Phillip Morris said its New Year’s resolution is
to give up cigarettes (http://nnw.fm/Q2Dc1) and took out full-page ads in
several newspapers in the United Kingdom that reiterated its ambition.
Altria Group Inc. (NYSE: MO) is another global tobacco company based in the
United States focused on addressing these same issues of reducing the health
effects of tobacco use. “Reduced risk” tobacco products are reportedly part of
Altria’s future, with many industry analysts expecting this category to be a
major growth driver in 2018 (http://nnw.fm/vr3Ys). Regulatory hurdles along with
limitations on marketing campaigns, a growing anti-smoking push and higher
excise taxes are all dragging tobacco companies down.
Leading tobacco leaf supply company Universal Corporation (NYSE: UVV) doesn’t
make cigarettes or tobacco products, but the Virginia-based company is still
affected by the public’s growing aversion to combustible cigarettes. Universal
states on its website that the company believes growth in world consumption of
cigarettes peaked several years ago and is declining. While its clients remain
the six largest tobacco companies in the world, Universal is also investing in
alternative forms of revenue (http://nnw.fm/0VKe0). The company’s AmeriNic joint
venture seeks to produce liquid nicotine for the vapor products industry, which
may prove to be a lucrative change from the conventional tobacco end market.
A Bright Future
Lexaria, which upgraded to the OTCQB Venture Market on January 4, 2018, expects
this to provide an unqualified positive opportunity for investors as the company
continues to build its disruptive technology and create innovative products for
the cannabis industry and nicotine-suppression markets.
“Lexaria has made notable progress over the past twelve months in all aspects of
its business, and will receive even more recognition by upgrading to OTCQX," CEO
Bunka stated in the press release announcing the uplisting. "Lexaria expects to
provide greater visibility and liquidity for our investors on OTCQX as we build
our disruptive technology innovations through 2018 and beyond."
For more information on Lexaria Bioscience, visit:
Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our
news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize
corporate news and information, (3) enhanced press release services, (4) social
media distribution and optimization services, and (5) a full array of corporate
communication solutions. As a multifaceted financial news and content
distribution company with an extensive team of contributing journalists and
writers, NNW is uniquely positioned to best serve private and public companies
that desire to reach a wide audience of investors, consumers, journalists and
the general public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting through the
overload of information in today’s market, NNW brings its clients unparalleled
visibility, recognition and brand awareness. NNW is where news, content and
information converge.
Please see full terms of use and disclaimers on the NetworkNewsWire website
applicable to all content provided by NNW, wherever published or re-published:
http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set
forth above. References to any issuer other than the profiled issuer are
intended solely to identify industry participants and do not constitute an
endorsement of any issuer and do not constitute a comparison to the profiled
issuer. FN Media Group (FNM) is a third-party publisher and news dissemination
service provider, which disseminates electronic information through multiple
online media channels. FNM is NOT affiliated with NNW or any company mentioned
herein. The commentary, views and opinions expressed in this release by NNW are
solely those of NNW and are not shared by and do not reflect in any manner the
views or opinions of FNM. Readers of this Article and content agree that they
cannot and will not seek to hold liable NNW and FNM for any investment decisions
by their readers or subscribers. NNW and FNM and their respective affiliated
companies are a news dissemination and financial marketing solutions provider
and are NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy any
security.
The Article and content related to the profiled company represent the personal
and subjective views of the Author, and are subject to change at any time
without notice. The information provided in the Article and the content has been
obtained from sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all such
information. None of the Author, NNW, FNM, or any of their respective
affiliates, guarantee the accuracy or completeness of any such information. This
Article and content are not, and should not be regarded as investment advice or
as a recommendation regarding any particular security or course of action;
readers are strongly urged to speak with their own investment advisor and review
all of the profiled issuer's filings made with the Securities and Exchange
Commission before making any investment decisions and should understand the
risks associated with an investment in the profiled issuer's securities,
including, but not limited to, the complete loss of your investment.
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and NNW and FNM undertake no obligation to update
such statements.
NetworkNewsWire (NNW) is affiliated with the Investor Based Brand Network (IBBN).
About IBBN
Over the past 10+ years we have consistently introduced new network brands, each
specifically designed to fulfil the unique needs of our growing client base and
services. Today, we continue to expand our branded network of highly influential
properties, leveraging the knowledge and energy of specialized teams of experts
to serve our increasingly diversified list of clients.
Please feel free to visit the Investor Based Brand Network (IBBN)
www.InvestorBasedBrandNetwork.com
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Media Contact:
FN Media Group, LLC
NNW@FinancialNewsMedia.com
+1-(954)345-0611
Source: NetworkNewsWire
2017 Wrap-Up by Lexaria's CEO
KELOWNA, BC -- January 8, 2018 -- Lexaria Bioscience Corp. (OTCQB:
LXRP)(CSE:
LXX.CN) (the
"Company" or "Lexaria") announces it's been quite an amazing year
for Lexaria stakeholders - the busiest and most productive we've had. I've
welcomed so many new shareholders and Lexaria fans in 2017 and I want to ensure
both our new followers as well as our long-term supporters remember just how
much we've achieved in the past year.
Financial Improvement
In mid-2016 our finances were in rough shape and our balance sheet was weak. I
made a promise to everyone back then that Lexaria's first priority was to ensure
we could survive as a strong and independent company. In October 2016 our first
patent was granted by the US Patent and Trademark Office (USPTO) and that event
- which we had been working on internally, quietly, for two years - changed
everything.
We've raised well over US$4 million in equity since then and paid off all our
debt. We never stooped to sign any toxic convertible finance deals; not for a
single minute did we forget that our first priority is to our shareholders and
our moral and fiduciary duties are to act in the best interest of shareholders.
Thus when we completed a brokered private placement early in the Spring of 2017
we did so at prices much closer to a 52-week high than to a 52-week low. We told
our shareholders repeatedly that, because we did not want to suffer through any
additional dilution, we would not complete
another financing in 2017: and we kept our word.
We remain disinterested in dilutive financings and will only contemplate
strategic equity that delivers more value to our shareholders than the monetary
equivalent.
Ongoing R&D
With our improved financial ability, we were able to announce a $1 million
budget for R&D using our patented DehydraTECH(TM) absorption and palatability
enhancing technology meant to build long term value - significantly more than
we've ever spent in the past. We continue to operate within that budget with
plans for a cannabidiol (CBD)-infused topical creamin vitro absorption test
scheduled for Jan-Feb; a nicotine-infused oral solution in vivo tolerability and
absorption test also scheduled for Jan-Feb; in-house formulation experiments for
other formulation enhancements and variants continuing on an ongoing basis; and
formulation optimization and testing with potential corporate clients also
continuing on an ongoing basis. In addition, we are pursuing a number of
intellectual property (IP) enhancement procedures also within our R&D budget as
we continually endeavour to broaden and expand our IP portfolio. As results from
current-phase experiments are produced we will be able to use our increased
knowledge to re-evaluate and enter more advanced phases of experimentation.
We also are progressing into second phase experimentation with our
2017-announced relationship with Canada's National Research Council. Progress
here has been measured to date and we expect it to continue throughout the year
to come. We announced an exciting set of tests to proceed in partnership with
the University of British Columbia (UBC) and were ready to proceed with the
launch of those tests in December, having recently completed the manufacturing
and quality control testing of all three of the required test articles.
Unfortunately, UBC has revised their policies for these sorts of tests which are
now on hold, but, we're working hard to either get those tests launched
substantially as planned, or make other arrangements to do so elsewhere.
Lexaria is content knowing we have sufficient funds in-hand to complete our
anticipated R&D projects and budget throughout 2018. We will continue to stretch
our funds as far as we can through partnerships with centers of higher learning
and through relationships in the private sector including with potential
licensees of our technology; in doing so, our R&D dollars are delivering far
more value than the headline figure would indicate.
California and Canada
The cannabis business environment is evolving rapidly and opportunities are
growing faster than a weed. Health Canada has issued about 84 cannabis licenses
in Canada with indications this could increase to a total of over 200 later in
2018: this is GREAT NEWS for Lexaria as licensed producers will increasingly be
searching for ways to differentiate and improve their products vs. the
competition.
Lexaria is ready for increased demand for its technology by Canadian licensed
cannabis producers in 2018 and is fully aware of the laws of supply and demand:
by restricting the number of technology usage licenses we will issue in Canada,
we expect the value our technology delivers to be even higher. We expect that
the "Powered by Lexaria" label will become highly sought by consumers and lead
to a greater likelihood of consumer success by our licensed partners.
Likewise, in California with its new legalized recreational market as of January
1, 2018, we expect demand for our technology to be strong. In both these newly
opening markets, Lexaria hopes to enter meaningful new license agreements that
will begin to provide the foundation of our operational success far into the
future. We've long said that Legalization Equals Regulation: and that regulation
is friendly to Lexaria's business model as it strongly incentivizes companies to
adopt performance enhancing technology.
Developments in California and Canada, to my eye, are proof that Lexaria's
business model is on the right track. I expect newly regulated markets in North
America and around the world to offer similar opportunities for technology
licensing. If successful, these are the relationships that could provide Lexaria
with a strong foundation for revenue growth.
The World Environment for CBD
The World Anti-Doping Agency (WADA) has exempted CBD from its 2018-list of
controlled substances for use by athletes. Meanwhile the World Health
Organization (WHO) has announced an overwhelming global response to questions it
posed in 2017 about de-regulating CBD. Lexaria submitted an extensive brief to
the WHO in this regard. The WHO is meeting to consider the matter in 2018 and I
believe will in fact deregulate and possibly de-schedule CBD entirely. This
could open the door to national governments lessening or removing restrictions
on CBD products in any number of national markets during 2018 and beyond, and
Lexaria is actively evaluating opportunities to expand commercialization of its
product offerings in developing markets beyond the USA accordingly.
It is in large part because of these long-term macro trends and evolutions of
governments regulatory bodies that Lexaria has taken large positions in
subsidiary companies that could benefit. In the Spring of 2017 we launched a
joint venture into a company that Lexaria owns 50% of: Ambarii Trade Corp. Over
time we hope that Ambarii will offer international opportunities for a class of
mouth-melt consumer products empowered with Lexaria's technology. In the Fall of
2017 we consolidated our ownership of PoViva Tea LLC from our previously held
51% holding that we grew this year to 100% ownership. PoViva has great potential
as a consumer brand for hemp-oil products but we at Lexaria have known for some
time that development and sale of hemp-based consumer products is a long-term
project that will require patience to produce significant returns. These
opportunities will start to bear fruit in 2018 and beyond.
We also introduced TurboCBDTM, our 100%-owned brand of hemp oil empowered with
Lexaria's unique technology blended with American Ginseng and Ginkgo in a
capsule format. The product has been a success and has taught us much about
incorporating our technology into a common form of consumer product. We are
contemplating development of additional varieties of TurboCBDTM as well as
international expansion for the product line.
Intellectual Property Creation
It wasn't lost on us that our focus on building core value within Lexaria would
be achieved with official recognition of Lexaria's IP. We witnessed this in late
in 2016 with our first US patent award; then again in the first half of 2017
with our first patent award in Australia; and more dramatically in November 2017
with our second, most comprehensive patent issuance in the USA. I expect
additional patent awards will be received by Lexaria in 2018, both in the USA
and internationally. Our patent and IP portfolio continues to expand and evolve
over time with alterations, modifications of existing patent applications and
R&D into continued new patent applications on the drawing board for 2018.
At this moment in time Lexaria has 33 patent applications pending around the
world, including 3 in each of Canada, Japan, Australia, China, India, and the
European Union; 12 applications in the USA; and 3 applications under the Patent
Cooperation Treaty. These numbers will continuously vary both up and down now
that we have so many applications active in so many regions. Considering that
the 2 patents granted in the USA and 1 granted in Australia have been as
impactful to Lexaria's present standing as they have, it is easy to understand
why we are so bullish on Lexaria's future with respect to additional
international and national patent awards.
The patent award that we announced on November 1, 2017 for the application of
our core technology to not just the cannabinoids we originally sought, but also
to vitamins, NSAIDs, and nicotine is arguably the most important value-creation
event - so far - in our company's history. Securing patent protection for this
IP was a fundamental requirement for Lexaria's long term growth and we are of
course expecting international recognition of this IP in 2018 and beyond.
Valuation Gains
To this day, current senior management of the Company has not sold a single
share of stock: we continue to believe strongly in the future of Lexaria and
that we have copious opportunity to continue to increase shareholder value and
Lexaria's valuation going forward. Although Lexaria's valuation has increased by
roughly 25x over the past two years - roughly from $0.08 to $0.40 in 2016 and
then from $0.40 to $2.00 during 2017 - I remain personally dissatisfied and will
not cease my goal of improving shareholder value until I believe Lexaria's
potential is fully valued.
In recent days we've announced that we have graduated from the OTCQB market -
where we've been traded for roughly twelve years - to the highest tier available
on the OTC Markets, the OTCQX market. This market is reserved for those
companies that can meet the highest financial and reporting standards imposed by
OTC Markets and we are pleased to have reached this threshold. We also filed an
S4 prospectus to redomicile our company from the USA to Canada, in order to take
advantage of what we believe will be enhanced opportunities available to
Canadian-domiciled companies where the regulatory and market framework for
companies operating in the cannabinoid products sector as our lead commercial
opportunity currently is amongst the most advanced and favorable in existence in
the world today.
A Look Ahead
As noted above, our plans for 2018 are full of R&D, IP pursuits, and expansion
of possibilities for hemp based consumer products. We also are investing more
time and effort into potential commercial relationships to utilize our patented
DehydraTECH(TM) technology and produce increased corporate revenues to Lexaria.
Most of our small base of revenue in 2016 came from selling consumer products
but we shifted that in 2017 to generate most of our revenue from technology
out-licensing. We expect that trend of a majority of our revenue to come from IP
out-licensing in 2018 to continue. And we hope to complete and announce a number
of commercial licensing relationships we currently have in process to grow our
corporate revenues as soon as possible.
As 2018 progresses we hope to both expand commercial adoption of our tech and
also introduce our tech for the first time to new sectors such as nicotine and
NSAID delivery. Stakeholders should keep in mind that these are long range plans
that will take time, testing and money to complete. Lexaria is always active
with a number of short term plans focused on short term results; and long term
plans designed to build strong foundations for future growth.
It truly takes time and often herculean efforts to achieve long lasting value
creation. Sometimes it may seem we are moving slowly but appearances might
obscure otherwise rampant internal valuation driving activity. Sometimes there
are dramatic value enhancements that are plainly obvious while at other times it
may take several quarters for effects to make themselves visible. Lexaria
remains thankful for our preponderance of thoughtful and patient stakeholders.
Lexaria has been on its current path for roughly four years and has experienced
good times and bad. I've come to know many of you personally during that time
and am humbled that you've stuck with us especially through those challenging
times: I happen to believe the "Lexaria Community" is different - and frankly,
better - than those of many other public companies. We're planning and preparing
for a raucous 2018 and I hope most of you are still part of our community a year
from now as we prepare to look back at what I hope and expect to be another
record-setting year.
Best wishes and good luck throughout 2018!
About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery
technology that promotes healthier ingestion methods, lower overall dosing and
higher effectiveness of lipophilic active molecules. Lexaria has multiple
patents pending in over 40 countries around the world and has patents granted in
the USA and in Australia for utilization of its DehydraTECHTM delivery
technology. Lexaria's technology provides increases in intestinal absorption
rates; more rapid delivery to the bloodstream; and important taste-masking
benefits, for orally administered bioactive molecules including cannabinoids,
vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other
molecules.
www.lexariabioscience.com
For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)
and on Facebookhttp://tinyurl.com/y8vzcaam
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(778) 796-1897
Source: Lexaria Bioscience Corp
Lexaria Upgrades to the OTCQX
Market
KELOWNA, BC -- January 4, 2018 -- Lexaria Bioscience Corp. (OTCQB:
LXRP)(CSE:
LXX.CN) (the
"Company" or "Lexaria") a drug delivery platform innovator,
announces it has qualified and is now trading on the OTCQX Best Market, operated
by OTC Markets Group.
The OTCQX market is reserved for proven companies that meet stringent financial
standards, provide thorough and timely news disclosure to investors, and are
sponsored by a qualified third-party advisor.OTCQX is recognized by the
Securities and Exchange Commission as an "established public market".
"Lexaria has made notable progress over the past twelve months in all aspects of
its business, and will receive even more recognition by upgrading to OTCQX,"
said Chris Bunka, Chief Executive Officer of Lexaria Bioscience Corp. "Lexaria
expects to provide greater visibility and liquidity for our investors on OTCQX
as we build our disruptive technology innovations
through 2018 and beyond."
Investors will find updated financial disclosure and Real-Time Level 2 quotes
for LXRP atwww.otcmarkets.com.
About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery
technology that promotes healthier ingestion methods, lower overall dosing and
higher effectiveness of lipophilic active molecules. Lexaria has multiple
patents pending in over 40 countries around the world and has patents granted in
the USA and in Australia for utilization of its DehydraTECHTM delivery
technology. Lexaria's technology provides increases in intestinal absorption
rates; more rapid delivery to the bloodstream; and important taste-masking
benefits, for orally administered bioactive molecules including cannabinoids,
vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other
molecules.
www.lexariabioscience.com
For regular updates, connect with Lexaria:
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(778) 796-1897
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not
historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: that
any additional stock warrants or stock options will be exercised. Such
forward-looking statements are estimates reflecting the Company's best judgment
based upon current information and involve a number of risks and uncertainties,
and there can be no assurance that other factors will not affect the accuracy of
such forward-looking statements. Factors which could cause actual results to
differ materially from those estimated by the Company include, but are not
limited to, government regulation, managing and maintaining growth, the effect
of adverse publicity, litigation, competition, the patent application and
approval process and other factors which may be identified from time to time in
the Company's public announcements and filings. There is no assurance that
existing capital is sufficient for the Company's needs or that it will be able
to raise additionalcapital. There is no assurance that Lexaria will successfully
complete any contemplated or existing technology license agreements; or that
results from any studies will be favorable or in any way support future business
activities of any kind.Scientific R&D is often unpredictable and unanticipated
results could emerge from any study and have a material impact.There is no
assurance that any planned corporate activity, scientific study, R&D, business
venture, or initiative will be pursued, or if pursued, will be successful. There
is no assurance that any of Lexaria's postulated uses, benefits, or advantages
for the patented and patent-pendingtechnology will in fact be realized in any
manner or in any part. No statement herein has been evaluated by the Food and
Drug Administration (FDA). Lexaria Energy Foods, Ambarii,
DehydraTECHTMtechnology and ViPovaTMproducts are not intended to diagnose,
treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Source: Lexaria Bioscience Corp
Merger and Acquisition Activity is Heating Up in the Cannabis Industry
New York, NY – December 7, 2017 –
NetworkNewsWire.com News
Coverage: Merger and acquisition (M&A) activity in the cannabis
industry is heating up, and market analysts point to several important factors
contributing to increased activity.
Profit
is always a central issue, and as the founders of companies established years
ago seek attractive exit strategies, new players are considering ways to enter
the field in a profitable way. The rapid evolution of technology and its
increasing application also serve as catalysts for M&A, as larger companies
pursue opportunities that are positioned for current or near-term commercial
availability. Such expertise and assets developed by smaller brands could
potentially turn them into attractive targets for M&A activity.
Lexaria Bioscience Corp. (OTCQX: LXRP) is one such potential
target due to its proprietary technology for improved taste, rapidity and
delivery of bioactive compounds, including cannabinoids. Other industry reps
that have made valuable contributions to cannabis product development include
Canopy Growth Corp. (OTC: TWMJF) (TSX: WEED), Aurora Cannabis, Inc. (OTC: ACBFF)
(TSX: ACB), Radient Technologies, Inc. (TSX-V: RTI) and Hemp, Inc. (OTC: HEMP).
As Canada prepares to legalize the recreational use of marijuana next summer,
the push for M&A becomes even greater. Since the beginning of the fourth quarter
of 2016, an average of approximately 3.2 deals have been closing per week well
into 2017 (http://nnw.fm/vC8CU). In comparison, the average for the same period
one year ago was approximately 1.4 deals. Analysts note an increase in interest
from Canadian companies that wish to cross the border to become a part of the
U.S. cannabis industry.
Generally, M&A activities focus on companies and facilities that already have
well-developed positions in the field. In 2017, one of the oldest marijuana
dispensaries in Denver sold to a Colorado enterprise (http://nnw.fm/ur6vC). The
fate of the two-best selling marijuana retailers in Washington was similar. The
initial price tag set for the two businesses was $50 million (http://nnw.fm/UTn2Y).
Developments on the Canadian market have also been pretty dynamic in 2017. The
trend will potentially be upheld in the year to come and strategic interest will
fall on innovators in the field of cannabis extraction and CBD oil delivery.
For
Lexaria Bioscience Corp. (OTCQX: LXRP), the company has several notches
in its belt that could stimulate its potential as an attractive acquisition
target. Lexaria is a revenue-generating biosciences company focused on improving
the delivery of bioactive compounds through gourmet foods. The primary
differentiator between Lexaria’s products and others on the market is the
company’s patented delivery technology for non-psychoactive cannabinoids.
In addition to being cost effective, the company’s DehydraTECH™ proprietary
technology has been proven in both the laboratory and market to enhance the
performance of beneficial compounds in ingestible products in what regards
smell, taste, action duration and bio-availability and absorption. This allows
for lower overall dosing and higher efficacy, a plus for cannabis suppliers and
consumers alike.
The technology works with all ingested forms of cannabinoids, making Lexaria an
enabler rather than a competitor, and allowing the company to develop
partnerships with various biotech companies for cannabinoid research and
development.
In October, Lexaria grew its portfolio of 19 international patent applications
when it received patent allowance for DehydraTECH™ as a delivery platform for
all cannabinoids, including (tetrahydrocannabinol) THC, fat soluble vitamins,
non-steroidal anti-inflammatory pain medications (“NSAIDs”) and even nicotine.
Upon formal patent issuance, the company will receive protection for its
technology until at least 2035, and Lexaria will be in the prime position to
accelerate its technology out-licensing activities in several key markets.
“This wide-ranging patent allowance from the USPTO exceeds our expectations.
This vastly expanded intellectual property protection will enable us to
aggressively pursue new business opportunities in 2018 such as what could be the
world’s first nicotine edibles for the smokeless tobacco industry, or enhanced
products for NSAID-derived pain management, as well as in the rapidly growing
cannabis market,” Lexaria CEO Chris Bunka stated in the press release (http://nnw.fm/2iPIn).
Because Lexaria’s patented lipid-delivery technology can be successfully applied
to cannabinoids, vitamins, NSAIDs and also tobacco, the company is positioned
for opportunity in several lucrative markets.
Global demand for tobacco and nicotine products continues to grow, placing the
global tobacco market at approximately $770 billion. However, demand for
alternative tobacco and nicotine products aimed at reducing the risks of smoking
is also growing at a rapid pace. Lexaria’s technology offers a safer, healthier
alternative to traditional nicotine delivery systems by allowing the infusion of
nicotine molecules with different edible food ingredients or in capsule formats
(http://nnw.fm/Xqw5T). Edible or capsule forms of nicotine have largely been
unsuccessful so far in terms of manufacturing, but Lexaria’s technology can
overcome any such challenges and lead to the creation of nicotine-infused
products without any dangerous side effects.
Currently, Lexaria is the only company in the world that holds a patent for the
improved delivery methodology. The patent is valid for the U.S. and Australia,
and it is currently pending for 40 other countries. As the company’s market
reach and application of technology grow, so does brand recognition and its
visibility among larger companies looking to add to their portfolios. This puts
Lexaria in an advantageous position when it comes to strategic industrial
partnerships and possible acquisition or merger.
Another sweet spot for Lexaria is Canada’s increasing favor toward cannabis.
Canadian regulators in November 2017 began discussing the legalization of
cannabinoid edibles and beverages for the first time, and the Canadian
government has committed to the date of July 1, 2018, for the nationwide
legalization of recreational marijuana. As regulators open up the markets in
2018 and 2019, Canadian licensed cannabis producers are facing explosive demand
for their products, and could significantly benefit from Lexaria's delivery
platform.
A recent investment into Canopy Growth (OTC: TWMJF) (TSX: WEED) by Constellation
Brands, the $40+ billion company behind Corona, Modelo and Svedka is one example
of how M&A activity within cannabis is crossing borders into the likes of
tobacco and alcohol, as Canada prepares to legalize marijuana for recreational
use (http://nnw.fm/zkGu5).
Canopy Growth has long been open to industry partnerships and business
interactions aimed at stabilizing its market position. In November 2017, the
company announced a distribution agreement with the Winnipeg-based Delta 9
Cannabis Inc. Delta 9 focuses its activity on growing small batch medical
cannabis strains for the purpose of developing a diversified range of products.
Also in November, Canopy Growth entered another strategic partnership with Green
House Holding North America Inc. and GHSC Trading B.V. for the purpose of
bringing new products to the Canadian market.
Notably, Lexaria’s patented technology could ensure leading market positions for
businesses like Canopy Growth, potentially serving as the fine line between
success and failure in an increasingly competitive environment.
Aurora Cannabis (OTCQX: ACBFF) (TSX: ACB) is another prominent player on the
Canadian market that demonstrates increased M&A and investment activity in the
cannabis industry. Aurora on November 24 announced the launch of a takeover bid
for CanniMed, which will enable the company to benefit from Aurora’s leadership
position in the Canadian cannabis market. Just a day earlier, Aurora announced
its acquisition of H2 Biopharma, a company recognized for its 48,000-square-foot
cannabis production facility located in the vicinity of Montreal. Also on
November 23, Aurora Cannabis announced the acquisition of Larssen Ltd. – a
company known for the creation of high-quality automated greenhouses.
Earlier this week Aurora Cannabis said it will increase its investment in
Radient Technologies (TSX-V: RTI) to a total of $12 million, echoing the need
for increased supply in the Canadian market.
"With multiple Aurora facilities coming online and ramping up production in the
coming quarters, as well as the anticipated export of cannabis oils and
preparations for the legalization of adult consumer use in Canada, Radient's
planned expansion positions both companies exceptionally well to accelerate
revenue growth," Aurora Cannabis CEO Terry Booth stated in the news release
(http://nnw.fm/JYs3k). "This investment reflects our strategy to build a
constellation of vertically integrated partners and subsidiaries, and we look
forward to jointly pursuing further expansion of market share in this exiting
space."
M&A activity isn’t just commonplace among industry giants like Constellation
Brand or Aurora Cannabis. Hemp, Inc. (OTC: HEMP) recently announced its
acquisition of specialized equipment and technology for enhancing the company’s
extraction operation that will be assembled shortly. Currently, Hemp Inc. has
the largest multi-purpose industrial hemp processing facility in the Western
Hemisphere with many investments in innovation as well as acquisitions of
specialized equipment over a long-time period. In August 2017, the company got
its NuAxon Tech CO2 supercritical extractor – an essential step towards the
completion of thorough extraction infrastructure that will allow for more
efficient CBD oil product manufacturing.
M&A activity will focus on unique assets and well-established facilities with
the potential to guarantee leadership positions on both the Canadian and the
international markets. As regulators continue to open up the cannabis industry,
they could fuel even higher rates of activity in 2018 and beyond. For companies
like Lexaria, this could mean an exponential amount of potential for licensing
agreements, key partnerships and potential acquisition activity.
To find out more about Lexaria Bioscience Corp. visit the company online at
Lexaria Bioscience Corp. (OTCQX: LXRP)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our
news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize
corporate news and information, (3) enhanced press release services, (4) social
media distribution and optimization services, and (5) a full array of corporate
communication solutions. As a multifaceted financial news and content
distribution company with an extensive team of contributing journalists and
writers, NNW is uniquely positioned to best serve private and public companies
that desire to reach a wide audience of investors, consumers, journalists and
the general public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting through the
overload of information in today’s market, NNW brings its clients unparalleled
visibility, recognition and brand awareness. NNW is where news, content and
information converge.
Please see full terms of use and disclaimers on the NetworkNewsWire website
applicable to all content provided by NNW, wherever published or re-published:
http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set
forth above. References to any issuer other than the profiled issuer are
intended solely to identify industry participants and do not constitute an
endorsement of any issuer and do not constitute a comparison to the profiled
issuer. FN Media Group (FNM) is a third-party publisher and news dissemination
service provider, which disseminates electronic information through multiple
online media channels. FNM is NOT affiliated with NNW or any company mentioned
herein. The commentary, views and opinions expressed in this release by NNW are
solely those of NNW and are not shared by and do not reflect in any manner the
views or opinions of FNM. Readers of this Article and content agree that they
cannot and will not seek to hold liable NNW and FNM for any investment decisions
by their readers or subscribers. NNW and FNM and their respective affiliated
companies are a news dissemination and financial marketing solutions provider
and are NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy any
security.
The Article and content related to the profiled company represent the personal
and subjective views of the Author, and are subject to change at any time
without notice. The information provided in the Article and the content has been
obtained from sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all such
information. None of the Author, NNW, FNM, or any of their respective
affiliates, guarantee the accuracy or completeness of any such information. This
Article and content are not, and should not be regarded as investment advice or
as a recommendation regarding any particular security or course of action;
readers are strongly urged to speak with their own investment advisor and review
all of the profiled issuer's filings made with the Securities and Exchange
Commission before making any investment decisions and should understand the
risks associated with an investment in the profiled issuer's securities,
including, but not limited to, the complete loss of your investment.
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and NNW and FNM undertake no obligation to update
such statements.
NetworkNewsWire (NNW) is affiliated with the Investor Based Brand Network (IBBN).
About IBBN
Over the past 10+ years we have consistently introduced new network brands, each
specifically designed to fulfil the unique needs of our growing client base and
services. Today, we continue to expand our branded network of highly influential
properties, leveraging the knowledge and energy of specialized teams of experts
to serve our increasingly diversified list of clients.
Please feel free to visit the Investor Based Brand Network (IBBN)
www.InvestorBasedBrandNetwork.com
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Media Contact:
FN Media Group, LLC
NNW@FinancialNewsMedia.com
+1-(954)345-0611
Source: NetworkNewsWire
____________________________
Recent LXRP Coverage:
Lexaria Bioscience Files
Innovative New Patent Application
KELOWNA, BC -- (Marketwired) -- Nov. 09, 2017 -- Lexaria Bioscience Corp. (OTCQB:
LXRP)(CSE:
LXX.CN) (the
"Company" or "Lexaria") a drug delivery platform innovator,
announces it has filed a new patent application with the US Patent and Trademark
Office (“USPTO”) utilizing the Lexaria DehydraTECHTM technology for delivery of
phosphodiesterase type 5 (PDE5) inhibitors - trade names of existing well-known
products include ViagraTM (sildenafil) and CialisTM (tadalafil).
In its new patent application, Lexaria has named the PDE5 inhibitors from the
group consisting of avanafil, lodenafil, mirodenafil, sildenafil (or analogs
thereof, for example, acetildenafil, hydroxyacetildenafil, or
dimethylsildenafil), tadalafil, vardenafil, udenafil, acetildenafil, and
thiomethisosildenafil. In addition, under the new patent application each of
these named molecules may be combined with a cannabinoid such as cannabidiol (“CBD”),
where the cannabinoid delivered in concert may provide complementary
vasodilatory activity beneficial together with the PDE5 inhibitor.
A common complaint of existing PDE5 delivery is the slow-acting nature of the
substances. Building on existing successful
research with cannabinoid delivery, Lexaria believes its patented DehydraTECHTM
technology will allow for faster acting treatments in many cases utilizing lower
dosage quantities.
As is true with Lexaria’s other patents and patent applications, the new PDE5
patent application is for the improved and more rapid delivery of the named
molecules and is meant to be complimentary to existing or newly planned consumer
products with a view to attracting prospective licensees or partners interested
in utilizing Lexaria’s technology in next generation commercial products.
Lexaria’s patented DehydraTECH™ technology is focused on improved delivery
methodologies of many commonly used API substances. As such, it provides an
additional layer of effectiveness that is designed to harmonize with the
intellectual property of third parties. Both patented and generic API substances
can utilize Lexaria’s patented technology. Lexaria’s long term strategy is to
partner with the world’s leading firms as they deliver best-of-class products to
their existing large consumer groups.
Separately, Lexaria announces that a number of existing stock options and
warrants have been exercised and Lexaria has received $69,736.50 from their
exercise. A total of 364,250 warrants were exercised at prices of $0.14, $0.42,
and $0.60; and 55,000 options were exercised at the price of $0.2273; for a
total of 419,250 common shares being issued. The warrants and options are being
exercised by third parties who are neither an officer nor director of the
Company. All amounts reported in US$. The Company has also issued 875 new 2-year
broker warrants with an exercise price of US$0.60.
Following issuance of these common shares, Lexaria will have 69,020,011 common
shares issued and outstanding. No commissions or placement fees have been paid
related to the funds received from these options and warrants exercised.
Proceeds will be used for general corporate purposes.
The securities referred to herein will not be or have not been registered under
the United States Securities Act of 1933, as amended, and may not be offered or
sold in the United States absent registration or an applicable exemption from
registration requirements.
About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery
technology that promotes healthier ingestion methods, lower overall dosing and
higher effectiveness of lipophilic active molecules. Lexaria has multiple
patents pending in over 40 countries around the world and was granted its first
patents in the USA and in Australia related to edible forms of cannabinoids.
Lexaria’s technology provides increases in intestinal absorption rates; more
rapid delivery to the bloodstream; and important taste-masking benefits, for
orally administered bioactive molecules including cannabinoids, vitamins,
non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com
For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)
and on Facebook http://tinyurl.com/y8vzcaam
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(778) 796-1897
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not
historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: that
any additional patent protection will be realized or that patent achievements
will deliver material results. Such forward-looking statements are estimates
reflecting the Company's best judgment based upon current information and
involve a number of risks and uncertainties, and there can be no assurance that
other factors will not affect the accuracy of such forward-looking statements.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation,
managing and maintaining growth, the effect of adverse publicity, litigation,
competition, scientific discovery, the patent application and approval process
and other factors which may be identified from time to time in the Company's
public announcements and filings. There is no assurance that existing capital is
sufficient for the Company's needs or that it will be able to raise additional
capital. There is no assurance the Company will be capable of developing,
marketing, licensing, or selling edible products containing nicotine or any
other active ingredient. There is no assurance that any planned corporate
activity, scientific research or study, business venture, technology licensing
pursuit, patent application or allowance, consumer study, or any initiative will
be pursued, or if pursued, will be successful. There is no assurance that any of
Lexaria’s postulated uses, benefits, or advantages for the patented and
patent-pending technology will in fact be realized in any manner or in any part.
No statement herein has been evaluated by the Food and Drug Administration
(FDA). Lexaria-associated products are not intended to diagnose, treat, cure or
prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Source: Lexaria Bioscience Corp
Bioabsorption Breakthrough Shows Promise for Tobacco, Cannabinoids, Medication
New York, NY – November 2, 2017 –
NetworkNewsWire.com News
Coverage: Double 2001 levels, Americans spent over $36 billion on
vitamins and nutritional supplements in 2016, contributing to a global dietary
supplements market expected to exceed $220 billion by the year 2022 (
http://nnw.fm/z8Bh1 ,
http://nnw.fm/qARU7 ). A noteworthy
characteristic of products within this booming sector is bio-absorbability. In
order for the body to utilize vitamins and minerals, they must disintegrate and
be quickly released. Otherwise, they are simply excreted, rendering them
ineffectual. A recent study
revealed
that over half of encapsulated micronutrients didn’t disintegrate within the
time needed for effective absorption (
http://nnw.fm/12CAq ), demonstrating a sizable underserved need within the
multi-billion-dollar industry.
Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and
patented a cost-effective lipophilic technology that addresses this issue,
serving as a delivery platform for all cannabinoids, fat soluble vitamins,
non-steroidal anti-inflammatory pain medications (“NSAIDs”), and even nicotine.
With proven efficacy for improved taste, rapidity, and delivery of bioactive
compounds, Lexaria is positioned to license its technology to tobacco giants
such as Philip Morris International, Inc. (NYSE: PM) and British American
Tobacco PLC (NYSE: BTI), as well as cannabinoid biopharmaceutical companies like
GW Pharmaceuticals PLC (NASDAQ: GWPH) and major drug companies such as Pfizer,
Inc. (NYSE: PFE).
Adding to its portfolio of 19 international patent applications filed
encompassing 44 countries,
Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) earlier this week
announced that it has received from the United States Patent and Trademark
Office (“USPTO”) a new Notice of Allowance that applies to the delivery of all
applied-for active pharmacological ingredients (“APIs”). As was the case with
Lexaria’s existing non-psychoactive cannabinoid patent, the company expects
formal patent issuance within three to four months, which is expected to provide
protection until at least 2035.
The issuance of the patent will enable Lexaria to accelerate its technology
out-licensing activities in several key markets.
The irony is that this R&D that originated in the cannabis is now finding use in
delivery of NSAIDs, vitamins and even nicotine.
“This wide-ranging patent allowance from the USPTO exceeds our expectations.
This vastly expanded intellectual property protection will enable us to
aggressively pursue new business opportunities in 2018 such as what could be the
world’s first nicotine edibles for the smokeless tobacco industry, or enhanced
products for NSAID-derived pain management, as well as in the rapidly growing
cannabis market,” Lexaria CEO Chris Bunka stated in the press release announcing
the news (http://nnw.fm/2iPIn).
According to the CDC, 36.5 million adults in the U.S. currently smoke tobacco,
while 16 million live with a smoking-related disease. The U.S. FDA earlier this
year submitted a proposal to reduce nicotine levels in cigarettes to
non-addictive levels in an effort to significantly reduce the effects of
tobacco-related diseases. As such, leading tobacco companies are pursuing
marketable alternatives to their combustible offerings, and Lexaria is uniquely
positioned to capture a share of this mammoth market with technology allows that
for the infusion of nicotine molecules within a wide range of edible food
ingredients or capsules.
Notably, current forms of nicotine delivery have mostly failed. The development
of readily absorbed nicotine-infused edible products could create smoke-free
cigarette alternatives and greatly improve upon the success of inhalation
smoking cessation programs. The expected FDA action makes tobacco giant Philip
Morris International Inc. (NYSE: PM), which manufactures and sells cigarettes
and other tobacco products globally, a potential licensee for edible, absorbable
nicotine replacement therapeutics.
Another potential tobacco company beneficiary of Lexaria’s technology is British
American Tobacco PLC (NYSE: BTI), which has invested more than $1 billion in
building its “Next Generation Products” business, an assortment of alternative
tobacco and nicotine products aimed at reducing the risks associated with
smoking conventional cigarettes. Looking to the future, BTI was among the first
international tobacco companies to launch an e-cigarette product in the UK.
Touted as a tobacco alternative, electronic cigarettes still rely on inhalation
for nicotine delivery, and the long-term health risk associated with
e-cigarettes remains in question. Bio-absorbable nicotine could provide much
safer and less expensive molecule delivery.
Lexaria’s potential in this market is best understood by examining the
application of the company’s technology to cannabinoids, as well as its
licensing strategy.
Medical cannabinoids have demonstrated therapeutic efficacy for a variety of
diseases and ailments; however, the human gastrointestinal tract doesn’t absorb
cannabinoids easily, causing wide deviation in onset times and effectiveness. To
achieve higher effectiveness, consumers usually default to smoking. The key
differentiator between Lexaria’s technology and older tech on the market is its
ability to enhance the absorption of orally-ingested cannabinoids while
improving the “unusual” taste and allowing for lower overall dosing with higher
efficacy. Furthermore, Lexaria’s lipophilic enhancement technology increases the
bio-absorption of cannabinoid edibles to between five and ten times that of
inhalation and reduces onset times by roughly 75% due to rapid bio-absorption
and potential liver bypass.
In what will only be strengthened by issuance of the aforenoted patent, Lexaria
uses a low-cost, high-margin license and royalty model of revenue generation.
Since its technology is complimentary to all ingested forms of cannabinoids and
potentially multiple other ingestible products, the company is positioned to
license its intellectual property to biopharmaceutical companies as a partner
rather than a competitor. In short, the enhanced technology provides an
additional layer of effectiveness designed to harmonize with the intellectual
property of third parties, such as GW Pharmaceuticals PLC (NASDAQ: GWPH), as
they deliver best-in-class products to their existing large consumer groups.
GW Pharmaceuticals is the world’s largest cannabinoid pharmaceutical company.
Recognized for its multiple sclerosis (MS) cannabinoid product, Sativex, GW
Pharmaceuticals is developing and commercializing multiple therapeutics from its
cannabinoid product platform across a range of disease areas. The company's lead
cannabinoid product candidate, Epidiolex, a liquid formulation of pure
plant-derived cannabidiol (CBD), is in phase III clinical trials for the
treatment of severe treatment-resistant epilepsy syndromes. Preliminary results
from the trials have produced encouraging results and, if approved, could bring
in blockbuster sales.
Beyond the cannabinoid sector, Lexaria sees considerable potential in applying
its delivery technology to many other consumer products, including NSAIDs like
Advil. More than 70 million prescriptions and more than 30 billion over-the
counter tablets of NSAIDs are sold annually in the United States alone. While
NSAIDs are effective in relieving pain, fever and inflammation, they can cause
unwanted and sometimes dangerous side effects. Given a timely and predictable
delivery system, biopharmaceutical giant Pfizer (NYSE: PFE), the maker of Advil,
could easily find multiple applications for Lexaria’s technology throughout its
global portfolio of medicines, vaccines and consumer health care products.
Lexaria is gaining considerable market traction with its expanding patent
portfolio, leveraging a unique technology that positions the company as a
potential partner to some of today’s leading consumer brands. Building on this
opportunity, Lexaria continues to explore additional technologies that could
deliver value to its growing portfolio of patented technologies which now has to
be considered one of the broadest in the industry.
For more information on Lexaria Bioscience Corp., please visit:
Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our
news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize
corporate news and information, (3) enhanced press release services, (4) social
media distribution and optimization services, and (5) a full array of corporate
communication solutions. As a multifaceted financial news and content
distribution company with an extensive team of contributing journalists and
writers, NNW is uniquely positioned to best serve private and public companies
that desire to reach a wide audience of investors, consumers, journalists and
the general public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting through the
overload of information in today’s market, NNW brings its clients unparalleled
visibility, recognition and brand awareness. NNW is where news, content and
information converge.
Please see full terms of use and disclaimers on the NetworkNewsWire website
applicable to all content provided by NNW, wherever published or re-published:
http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set
forth above. References to any issuer other than the profiled issuer are
intended solely to identify industry participants and do not constitute an
endorsement of any issuer and do not constitute a comparison to the profiled
issuer. FN Media Group (FNM) is a third-party publisher and news dissemination
service provider, which disseminates electronic information through multiple
online media channels. FNM is NOT affiliated with NNW or any company mentioned
herein. The commentary, views and opinions expressed in this release by NNW are
solely those of NNW and are not shared by and do not reflect in any manner the
views or opinions of FNM. Readers of this Article and content agree that they
cannot and will not seek to hold liable NNW and FNM for any investment decisions
by their readers or subscribers. NNW and FNM and their respective affiliated
companies are a news dissemination and financial marketing solutions provider
and are NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy any
security.
The Article and content related to the profiled company represent the personal
and subjective views of the Author, and are subject to change at any time
without notice. The information provided in the Article and the content has been
obtained from sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all such
information. None of the Author, NNW, FNM, or any of their respective
affiliates, guarantee the accuracy or completeness of any such information. This
Article and content are not, and should not be regarded as investment advice or
as a recommendation regarding any particular security or course of action;
readers are strongly urged to speak with their own investment advisor and review
all of the profiled issuer's filings made with the Securities and Exchange
Commission before making any investment decisions and should understand the
risks associated with an investment in the profiled issuer's securities,
including, but not limited to, the complete loss of your investment.
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and NNW and FNM undertake no obligation to update
such statements.
NetworkNewsWire (NNW) is affiliated with the Investor Based Brand Network (IBBN).
About IBBN
Over the past 10+ years we have consistently introduced new network brands, each
specifically designed to fulfil the unique needs of our growing client base and
services. Today, we continue to expand our branded network of highly influential
properties, leveraging the knowledge and energy of specialized teams of experts
to serve our increasingly diversified list of clients.
Please feel free to visit the Investor Based Brand Network (IBBN)
www.InvestorBasedBrandNetwork.com
Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Media Contact:
FN Media Group, LLC
NNW@FinancialNewsMedia.com
+1-(954)345-0611
News Source: NetworkNewsWire
____________________________
Recent LXRP Coverage:
Lexaria Bioscience Receives
Groundbreaking U.S. Patent Allowance for its DehydraTECH™ Delivery of THC,
NSAIDs, Nicotine and Vitamins.
KELOWNA, BC -- (Marketwired) -- Oct. 31, 2017 -- Lexaria Bioscience Corp. (OTCQB:
LXRP)(CSE:
LXX.CN) (the
"Company" or "Lexaria") a drug delivery platform innovator,
announces it has received a new Notice of Allowance from the United States
Patent and Trademark Office (“USPTO”) for the use of its technology as a
delivery platform for all cannabinoids including THC; fat soluble vitamins; non
steroidal anti-inflammatory pain medications (“NSAIDs”); and nicotine.
This Notice of Allowance applies to the delivery of all active pharmacological
ingredients (“APIs”) Lexaria had been seeking. While Lexaria has always had
confidence in its patent applications, the rapid allowance for this broad API
applicability is significantly ahead of Company expectations. As was true with
the Company’s existing non-psychoactive cannabinoid patent that was granted in
2016, Lexaria expects formal patent issuance within three to four months which
is expected to provide protection until at least 2035.
Under USPTO practice, there is no opposition period between allowance and
issuance. The patent application number is 15/225,799, “Food and Beverage
Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof”.
Lexaria also continues to advance all its additional patent applications in
various countries as it levers patent success in
the USA. For example, one of the Company’s patent applications has recently
entered the active patent investigation phase in China.
“Issuance of this broad patent will give Lexaria the ability to ramp up our
technology out-licensing activities especially within the pharmaceutical sector
where the expanded API capacity of our DehydraTECH™ delivery platform will be
most applicable,” said John Docherty, President.
“This wide-ranging patent allowance from the USPTO exceeds our expectations,”
said Chief Executive Officer Chris Bunka. “This vastly expanded intellectual
property protection will enable us to aggressively pursue new business
opportunities in 2018 such as what could be the world’s first nicotine edibles
for the smokeless tobacco industry, or enhanced products for NSAID-derived pain
management, as well as in the rapidly growing cannabis market.”
Lexaria’s patented DehydraTECH™ technology is focused on improved delivery
methodologies of many commonly used API substances. As such, it provides an
additional layer of effectiveness that is designed to harmonize with the
intellectual property of third parties. Both patented and generic API substances
can utilize Lexaria’s patented technology. Lexaria’s long term strategy is to
partner with the world’s leading firms as they deliver best-of-class products to
their existing large consumer groups.
Lexaria is presently investigating and will continue to pursue additional
technologies that could deliver value to its growing portfolio of patented
technologies.
About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery
technology that promotes healthier ingestion methods, lower overall dosing and
higher effectiveness of lipophilic active molecules. Lexaria has multiple
patents pending in over 40 countries around the world and was granted its first
patents in the USA and in Australia related to edible forms of cannabinoids.
Lexaria’s technology provides increases in intestinal absorption rates; more
rapid delivery to the bloodstream; and important taste-masking benefits, for
orally administered bioactive molecules including cannabinoids, vitamins,
non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com
For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)
and on Facebook http://tinyurl.com/y8vzcaam
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(778) 796-1897
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not
historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: that
any additional patent protection will be realized or that patent achievements
will deliver material results. Such forward-looking statements are estimates
reflecting the Company's best judgment based upon current information and
involve a number of risks and uncertainties, and there can be no assurance that
other factors will not affect the accuracy of such forward-looking statements.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation,
managing and maintaining growth, the effect of adverse publicity, litigation,
competition, scientific discovery, the patent application and approval process
and other factors which may be identified from time to time in the Company's
public announcements and filings. There is no assurance that existing capital is
sufficient for the Company's needs or that it will be able to raise additional
capital. There is no assurance the Company will be capable of developing,
marketing, licensing, or selling edible products containing nicotine or any
other active ingredient. There is no assurance that any planned corporate
activity, scientific research or study, business venture, technology licensing
pursuit, patent application or allowance, consumer study, or any initiative will
be pursued, or if pursued, will be successful. There is no assurance that any of
Lexaria’s postulated uses, benefits, or advantages for the patented and
patent-pending technology will in fact be realized in any manner or in any part.
No statement herein has been evaluated by the Food and Drug Administration
(FDA). Lexaria-associated products are not intended to diagnose, treat, cure or
prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Source: Lexaria Bioscience Corp
Advances in Drug Delivery Hold the Promise of Reducing Inevitable Side Effects
New York, NY – September 19, 2017 –
NetworkNewsWire.com News
Coverage: The hazards of pharmacology have hardly changed since
Paracelsus, a famous Renaissance physician, astoundingly declared that it was
only the dosage that
separated
a medicine from a poison, bundled with adverse side effects. Despite
considerable advances in medicine, many medications are still as injurious as
their Renaissance precursors. Nevertheless, recent developments in drug delivery
technologies increasingly suggest that safer, more efficient treatment options
are on the horizon. At the core of this potential are cannabinoids. Developments
in this rapidly growing segment of the medical marijuana market are pioneered by
a vast number of innovators, including
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX), GW Pharmaceuticals
(NASDAQ: GWPH), Zynerba Pharmaceuticals (NASDAQ: ZYNE), Cara Therapeutics
(NASDAQ: CARA) and Philip Morris (NYSE: PM), all of which are invested in the
cannabis space.
Research findings in the cannabinoid field continue to astonish and elate. In
August 2017,
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) announced (
http://nnw.fm/h7aG8 ) the world's first
clinical study on human volunteers of cannabidiol (CBD) within Lexaria's high
absorption TurboCBD™ product. The study will evaluate the effects of CBD on
cardiovascular health and cognitive function. Lexaria’s TurboCBD, a brand of
technologically enhanced, high absorption hemp oil capsules, came to market in
March 2017. Its CBD content is fortified with high-quality American ginseng and
ginkgo biloba for support of enhanced focus and memory, and reduced stress and
fatigue.
TurboCBD capsules contain a combination of CBD and minute quantities of long
chain fatty acids like sunflower oil, utilizing a proprietary technology to
create an amalgam that increases the ability of the human gastrointestinal
system to absorb CBD. In vitro and human focus study testing has shown increases
in CBD absorption using Lexaria’s technology by as much as 5-10 times more than
conventional preparations. Those studies also demonstrated rapid onset of action
in as little as 15 minutes.
The TurboCBD study is designed to test a number of hypotheses expected to follow
after its supplementation: (i) that circulating CBD and nitric oxide will
increase in both young and old participants; (ii) that glucose and blood
pressure will
remain stable; and (iii) that vascular function, and cognitive and physical
exercise performance will improve to a greater extent in older participants. The
study will be conducted by researchers at the University of British Columbia,
which has consistently been ranked as one of the top three universities in
Canada. The institution is also considered one of the top research universities
in the world and has conducted several earlier studies in the cannabis sector,
available for review at
http://nnw.fm/o8O9a
Lexaria has also developed and commercialized a patented and cost-effective
delivery technology, DehydraTECH™, which has been both laboratory and market
proven to enhance the performance of beneficial compounds in ingestible products
across four categories: taste, smell, speed of action, and bio-absorption and
bio-availability.
At present, Lexaria is the only company in the world that has been awarded a
patent for the improved (oral or ingestible, including pills) delivery of all
non-psychoactive cannabinoids. Patents have been awarded in the U.S. and
Australia and are pending in 40 more countries. This puts the company in the
unusually advantageous position of owning proprietary technology that can
deliver a vast range of non-psychoactive cannabinoid-based drugs.
Notably, because Lexaria’s technology is complimentary to all ingested forms of
cannabinoids, the company is positioned to license its intellectual property to
clinical-stage biotechnology companies, becoming an enabler – rather than a
competitor - that works with other research and development pertaining to
cannabinoids.
Collaboration with a company like GW Pharmaceuticals (NASDAQ: GWPH), for
example, would could yield considerable outcomes. The British company, best
known for its multiple sclerosis (MS) cannabinoid product, Sativex, is working
feverishly to bring another to market. Currently, its lead cannabinoid product
candidate Epidiolex is in phase III clinical trials. This drug is a proprietary
oral solution of pure plant-derived cannabidiol (CBD) for the treatment of
severe, orphan, early-onset, treatment-resistant epilepsy syndromes including
Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC)
and Infantile Spasms (IS).
Also developing treatments for epileptic conditions, with rather less
encouraging outcomes than GW Pharmaceuticals, is Zynerba Pharmaceuticals
(NASDAQ: ZYNE). In August 2017, the company published disappointing results of
phase II studies of its cannabidiol (CBD) product, ZYN002, aimed at treating
adult epilepsy patients with focal seizures. Since CBD has shown some promise in
reducing epileptic seizures, as in the GW Pharmaceutical studies, this raises
the possibility that Zynerba’s setback may be due, not to the payload, but the
delivery system. ZYN002 employs a transdermal gel that is applied topically on
the surface of the skin. However, an oral delivery system, like the one
developed by Lexaria, may prove more effective.
Cara Therapeutics (NASDAQ: CARA) is another biotech now coming to terms with
disappointing clinical trial results. Trials for an oral formulation of its drug
candidate CR845, an opioid derivative, studied in osteoarthritis patients, did
not turn out so well. However, the study tested patients on low dosages (1.0 mg
and 2.5 mg) of CR845 taken orally. Higher oral dosages and CR845 taken
intravenously have shown more promising outcomes. The company’s research into
opioids has spilled over into cannabinoids. Current preclinical research
involves CR701, a cannabinoid receptor agonist, designed to treat chronic pain.
The incentive to develop cannabinoid products to treat chronic pain is driven,
in part, by the opioid epidemic. While opioid overdose deaths are in the tens of
thousands, there appears to be no clearly documented account of anyone dying
from an overdose of marijuana.
Smoking marijuana is, of course, one method proven to deliver cannabinoids
effectively. Alas, the now well-known deleterious effects on the respiratory
system are spurring efforts to develop other delivery mechanisms, such as
non-smoke cigarettes, which perhaps is why Philip Morris International (NYSE:
PM) invested $20 million in Israeli startup Syqe Medical. The company
manufactures delivery devices for cannabis, like its inhaler. Syqe’s
pocket-sized Inhaler delivers precision dosages of its payload: 100 micrograms,
every time the device is activated. This overcomes a major barrier to adoption
of medical cannabis by doctors: the lack of standardization in dosage regimens.
Syqe has tested a similar device in hospitals in a clinical trial that
demonstrated its dosing precision superiority to other modes of THC
administration. With Philip Morris’ involvement, nicotine may just be next.
As the research into cannabinoids continues to unearth excitingly novel ways to
treat a variety of medical conditions, delivery systems are proving to be just
an important as payloads. As a result, companies with advanced delivery systems,
like Lexaria, are likely to find cannabinoid biotechs beating that proverbial
path to their door.
For more information on Lexaria Bioscience please visit:
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our
news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize
corporate news and information, (3) enhanced press release services, (4) social
media distribution and optimization services, and (5) a full array of corporate
communication solutions. As a multifaceted financial news and content
distribution company with an extensive team of contributing journalists and
writers, NNW is uniquely positioned to best serve private and public companies
that desire to reach a wide audience of investors, consumers, journalists and
the general public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting through the
overload of information in today’s market, NNW brings its clients unparalleled
visibility, recognition and brand awareness. NNW is where news, content and
information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website
applicable to all content provided by NNW, wherever published or re-published:
http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set
forth above. References to any issuer other than the profiled issuer are
intended solely to identify industry participants and do not constitute an
endorsement of any issuer and do not constitute a comparison to the profiled
issuer. FN Media Group (FNM) is a third-party publisher and news dissemination
service provider, which disseminates electronic information through multiple
online media channels. FNM is NOT affiliated with NNW or any company mentioned
herein. The commentary, views and opinions expressed in this release by NNW are
solely those of NNW and are not shared by and do not reflect in any manner the
views or opinions of FNM. Readers of this Article and content agree that they
cannot and will not seek to hold liable NNW and FNM for any investment decisions
by their readers or subscribers. NNW and FNM and their respective affiliated
companies are a news dissemination and financial marketing solutions provider
and are NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy any
security.
The Article and content related to the profiled company represent the personal
and subjective views of the Author, and are subject to change at any time
without notice. The information provided in the Article and the content has been
obtained from sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all such
information. None of the Author, NNW, FNM, or any of their respective
affiliates, guarantee the accuracy or completeness of any such information. This
Article and content are not, and should not be regarded as investment advice or
as a recommendation regarding any particular security or course of action;
readers are strongly urged to speak with their own investment advisor and review
all of the profiled issuer's filings made with the Securities and Exchange
Commission before making any investment decisions and should understand the
risks associated with an investment in the profiled issuer's securities,
including, but not limited to, the complete loss of your investment.
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and NNW and FNM undertake no obligation to update
such statements.
Media Contact e-mail: FN Media Group, LLC - editor@financialnewsmedia.com
(954)345-0611
News Source: NetworkNewsWire
Landmark M&A Deals Continue to Shape Big Pharma
New York, NY – September 6, 2017 –
NetworkNewsWire.com News
Coverage: Merger and acquisition activity has played a massive role in
the formation of the pharmaceutical industry as it exists today. Historic deals,
like Pfizer’s 2009 purchase of pharmaceutical giant Wyeth for $68 billion and
Glaxo Wellcome’s purchase of SmithKline Beecham for $76 billion in 2000, have
created a consolidated market that’s often driven forward by the innovations of
smaller companies.
Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP), with its
promising intellectual property portfolio focused on revolutionizing the
delivery of a variety of molecules to the human body, is well-positioned to
continue on this history of acquisition in the
pharmaceutical
space, following in the footsteps of companies like Derma Sciences, Inc., which
was acquired by Integra LifeSciences Holdings Corporation (NASDAQ: IART) for
approximately $200 million, and CoLucid Pharmaceuticals, Inc., which was
acquired by Eli Lilly and Company (NYSE: LLY) in a landmark $960 million deal.
With analyst rumblings pointing toward additional high-profile buyouts of
industry upstarts like ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) and Incyte
Corp. (NASDAQ: INCY), the time to cash in on the next Big Pharma acquisition
could be at hand.
While the acquisition frenzy in pharmaceuticals spans the entirety of the
colossal global industry, few subsectors have demonstrated more potential for
promising upstarts than the medicinal cannabis market. Projected by
Arcview Market Research to
eclipse $20.2 billion in North American sales by 2021, the legal marijuana
industry, including both medicinal and recreational markets, is expected to
create more than a quarter of a million jobs by 2020, outpacing economic
mainstays like manufacturing, utilities and government positions. This forecast
expansion has already set the stage for a number of industry acquisitions, many
of which have taken place in the soon-to-be federally legalized Canadian market.
One such is example Canopy Growth Corp.’s April
acquisition of rTrees Producers Limited, a late-stage Access to Cannabis for
Medical Purposes Regulations (“ACPMR”) applicant. The rTrees acquisition brought
a 90,000 square foot indoor growing facility with considerable room for
expansion under Canopy Growth’s already sizable umbrella, expanding upon the
market presence of the first Canadian cannabis company to achieve a $1 billion
market valuation.
Other industry players have followed Canopy Growth’s lead. In late July, Aurora
Cannabis announced plans to make a strategic investment in Hempco Food and
Fiber, Inc., one of the world’s largest producers of industrial hemp products.
Earlier that same month, Canadian cannabis producer Invictus MD Strategies Corp.
invested $5.5 million in AB Ventures, Inc. to fund the costs of licensing
approval under the ACMPR and construction of related production facilities.
Similar M&A deals were recently completed by Aphria, which invested $11.5
million in endocannabinoid-focused pharmaceutical company Scientus Pharma in
mid-August, and Maricann Group, Inc., which recently announced its acquisition
of biotech company NanoLeaf Technologies for total transaction consideration of
C$40.1 million. The NanoLeaf transaction is particularly intriguing for
prospective investors of
Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) , as NanoLeaf possesses
“the licensing rights to a number of globally patented technologies that provide
proven pharmaceutical, nutraceutical, cosmetic and functional beverage drug
delivery formulations.”
This recent industry activity highlights the rising demand for innovative and
marketable offerings targeting the burgeoning cannabis sector, but they fail to
capture the scale of a potential Lexaria Bioscience transaction. This is
because of the wide-ranging applications of Lexaria’s technology platform. To
date, the company has noted potential applications for its
lipid-based
molecular delivery technology that include NSAIDs, nicotine, vitamins and
cannabinoids – applications that are supported by 19 currently-pending patents
filed in more than 40 countries. According to biotech analysis firm
EvaluatePharma,
the global market for NSAIDs was valued at $11.4 billion in 2014. Meanwhile, the
global market for vitamins in on course to reach
$9.3 billion by 2020, the market for alternative nicotine delivery
technologies is at an all-time high following
recent FDA proposals, and consumer sales of cannabinoids are expected to
reach
$2.1 billion by 2020. All told, the market potential for Lexaria’s flagship
platform could be huge.
It has been precisely this potential, alongside numerous clinical, financial and
IP developments, that has driven Lexaria’s growth in recent months. On July 18,
the company announced ( http://nnw.fm/wI0LB )
that the Australian Patent Office granted a patent protecting its method of
improving absorption, speed of onset and taste of cannabinoid active agents in
edible products. This milestone was particularly noteworthy in that it followed
Lexaria’s
announcement of a $1 million combined R&D program aimed at examining
improvement in absorption offered by its technology for several groups of
molecules, including NSAIDs, nicotine, vitamins and cannabinoids. Just last
week, the company took a major step toward maximizing on the value of its
patented technology by announcing the
world’s first clinical study of human volunteers of CBD within its high
absorption TurboCBD™ product.
“Lexaria is proud to be advancing our collective knowledge of the benefits of
CBD specifically showcasing the benefits of Lexaria's unique patented delivery
technology,” Chris Bunka, CEO of Lexaria, stated in the news release announcing
the study. “Results will advance Lexaria's ability to custom design products
that increase the leading performance our technology already offers to
customers.”
Strengthening Lexaria’s status as a promising acquisition target is its current
cash position. The company has outlined a number of moves to bolster its balance
sheet in recent months, most notably its $1 million raise from warrant exercise
originally
announced on May 19. In total, Lexaria raised over $3 million in the past
nine months in a strategic effort to capitalize on the growth of both the
pharmaceutical industry as a whole and, perhaps more importantly, the cannabis
sector. With funding in place through 2019, according to Bunka, Lexaria has the
IP and the capital needed to properly demonstrate the marketability of its
lipid-based delivery technology while working with prospective licensees and
resellers to maximize returns for early investors.
Recent acquisitions in the pharmaceuticals industry highlight the potential
upside Lexaria presents to the investment community. Derma Sciences, Inc., for
example, operated as a tissue regeneration company at the forefront of research
and innovation for the management of acute and chronic wounds prior to its
acquisition by Integra LifeSciences Holdings Corp. (NASDAQ: IART) in January
of this year. In a
slide deck issued following the acquisition, IART noted Derma’s “line of
products with patented technologies,” including multiple offerings targeting the
burn and wound management market, as a key driver for the transaction. Insights
from medical technology analysis firm
MedMarket Diligence, LLC suggest that this market is currently growing at a
rate of 3.1 percent annually, providing a fertile runway for future sales growth
in the space. For comparison, the cannabinoid market, which is just one of many
potential indications for Lexaria’s molecular delivery technology, is expected
to climb
700 percent from 2016-2020.
Eli Lilly and Company’s (NYSE: LLY) March acquisition of CoLucid
Pharmaceuticals, Inc. serves as another example of the aggressive M&A strategy
employed by some of the most recognizable names in Big Pharma. At the time of
the deal, David R. Ricks, president and chief executive officer of Eli Lilly,
noted that the purchase would “enhance Lilly's existing pain management
portfolio and add a potential near-term launch to [its] late-stage pipeline.”
This late-stage addition is lasmiditan, an oral tablet that’s currently being
evaluated in phase III clinical trials for the acute treatment of migraine
headaches in adults. Lasmiditan was actually originally developed by Eli Lilly,
but it was licensed to CoLucid in 2005 as part of Lilly’s strategic move away
from the pain management market. On top of highlighting the evolving strategies
of Big Pharma players to capitalize on industry trends – including cannabis
painkillers and related cannabinoid products – the CoLucid acquisition’s focus
within the migraine drug market falls well within earshot of Lexaria’s diverse
portfolio of potential applications for its lipid-based delivery technology.
In both of these cases, high-dollar acquisitions were fueled by strong
intellectual property positions targeting inviting markets within the
pharmaceutical industry. This trend rings true when studying other upstart
companies that could be in line for big time buyouts. A buyout of ACADIA
Pharmaceuticals, Inc. (NASDAQ: ACAD) has been rumored for months, with the
company having reportedly received an offer from AstraZeneca in February and
interest from Pfizer related to its lead product NUPLAZID®, the only significant
compound in the company’s development pipeline. Approved by the FDA for the
treatment of hallucinations and delusions associated with Parkinson’s disease,
NUPLAZID® is currently in late stage trials for similar symptoms in Alzheimer’s
and schizophrenia, giving it the potential to address a massive and growing
global market. The company’s stock closed at $36.16 on September 1, and reports
from Seeking Alpha suggest that ACADIA’s management team is pushing for a
substantial premium for a potential buyout in the range of “$55 to $60 a share.”
Incyte Corp. (NASDAQ: INCY) is another prime buyout target, as reported in an
editorial piece published by MarketWatch. “Incyte is a throwback to what biotech
companies were meant to be,” RBC Capital Markets analyst Simos Simeonidis told
MarketWatch. “It’s built on ‘great science’ that has helped it develop several
drugs, and it continually reinvests in its own research.” Incyte’s main product,
Jakafi, is an FDA-approved medication used to treat rare blood cancers. Back in
March, analysts speculated that Gilead was close to an agreement to acquire
Incyte. Although that deal has not yet come to fruition, the Delaware-based
company offers a combination of growing revenues and strong R&D programs that
makes it a solid acquisition target, particularly as disappointing clinical data
from competing trials strengthen the revenue outlook of Incyte’s leading
product.
As demonstrated by recent industry activity, Big Pharma’s biggest names stay
active on the M&A front, especially as it relates to first-of-their-kind
advancements in promising markets. Continued interest in the pipelines of
upstarts like ACADIA Pharmaceuticals and Incyte Corporation paints an intriguing
picture as Lexaria Bioscience progresses with the world’s first clinical study
of CBD within its high absorption TurboCBD™ product. With a strong balance sheet
and an increasingly diverse and wide-reaching IP portfolio targeting some of the
industry’s highest growth verticals, Lexaria should be on the radar of any
investor hoping to cash in on the M&A deal-making bonanza that could be on the
horizon.
For more information on Lexaria Bioscience Corp., please visit:
Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our
news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize
corporate news and information, (3) enhanced press release services, (4) social
media distribution and optimization services, and (5) a full array of corporate
communication solutions. As a multifaceted financial news and content
distribution company with an extensive team of contributing journalists and
writers, NNW is uniquely positioned to best serve private and public companies
that desire to reach a wide audience of investors, consumers, journalists and
the general public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting through the
overload of information in today’s market, NNW brings its clients unparalleled
visibility, recognition and brand awareness. NNW is where news, content and
information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website
applicable to all content provided by NNW, wherever published or re-published:
http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set
forth above. References to any issuer other than the profiled issuer are
intended solely to identify industry participants and do not constitute an
endorsement of any issuer and do not constitute a comparison to the profiled
issuer. FN Media Group (FNM) is a third-party publisher and news dissemination
service provider, which disseminates electronic information through multiple
online media channels. FNM is NOT affiliated with NNW or any company mentioned
herein. The commentary, views and opinions expressed in this release by NNW are
solely those of NNW and are not shared by and do not reflect in any manner the
views or opinions of FNM. Readers of this Article and content agree that they
cannot and will not seek to hold liable NNW and FNM for any investment decisions
by their readers or subscribers. NNW and FNM and their respective affiliated
companies are a news dissemination and financial marketing solutions provider
and are NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy any
security.
The Article and content related to the profiled company represent the personal
and subjective views of the Author, and are subject to change at any time
without notice. The information provided in the Article and the content has been
obtained from sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all such
information. None of the Author, NNW, FNM, or any of their respective
affiliates, guarantee the accuracy or completeness of any such information. This
Article and content are not, and should not be regarded as investment advice or
as a recommendation regarding any particular security or course of action;
readers are strongly urged to speak with their own investment advisor and review
all of the profiled issuer's filings made with the Securities and Exchange
Commission before making any investment decisions and should understand the
risks associated with an investment in the profiled issuer's securities,
including, but not limited to, the complete loss of your investment.
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and NNW and FNM undertake no obligation to update
such statements.
Media Contact e-mail: FN Media Group, LLC - editor@financialnewsmedia.com
(954)345-0611
News Source: NetworkNewsWire
University of British Columbia
to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of
Lexaria's TurboCBD(TM)
KELOWNA, BC -- (Marketwired) -- Aug 31, 2017 -- Lexaria Bioscience Corp. (OTCQB:
LXRP)(CSE:
LXX.CN) (the
"Company" or "Lexaria") announces the world's first clinical
study on human volunteers of cannabidiol (CBD) within Lexaria's high absorption
TurboCBD™ product, to evaluate its effects on both cardiovascular health and
cognitive function.
The study will have a double-blind and placebo controlled cross-over design
measuring effects both after a single dose, and also after 7 days of daily
dosing in 24 volunteers. The study hypothesises that, following TurboCBD™
supplementation, circulating CBD and nitric oxide will increase in both young
and old participants; that glucose and blood pressure will remain stable; and
that vascular function, and cognitive and physical exercise performance will
improve to a greater extent in older participants. This research study has been
approved by the Clinical Research Ethics Board at the University of British
Columbia ("UBC").
Professor Philip Ainslie, PhD, Co-Director of the Centre for Heart, Lung and
Vascular Health, UBC Okanagan Campus,
Kelowna, Canada, will be Principal Investigator of a team of co-investigators.
UBC has consistently been ranked one of the top three universities in Canada,
has over 62,000 students on two campuses, and is further considered one of the
top research universities in the world. UBC has conducted several earlier
studies in the cannabis sector, available for review at https://news.ubc.ca/tag/marijuana/.
This advanced study will utilize the latest clinical evaluation techniques to
provide pharma-level pharmacokinetic and pharmacodynamic performance data of
TurboCBD™, including blood sampling, physiological measures, cognitive function
testing, vascular function testing, and exercise performance testing. Outcome
measurements will include circulating CBD and nitric oxide markers, plasma
glucose, plasma insulin, blood pressure, heart rate, respiration, peripheral and
brain blood flow and a battery of neuropsychological performance tests.
Dr. Philip Ainslie comments that, "This study gives us a great opportunity to
obtain world class clinical data on the health and performance benefits of
cannabidiol using Lexaria's unique high absorption TurboCBD™ capsules in our
state of the art laboratories. It is very exciting to be one of the first -- if
not the first -- to conduct these kinds of studies in Canada. The potential
implications of the study are far-reaching: from understanding the fundamental
biological mechanism(s) of high absorption CBD in humans, to how this might
influence blood vessel physiology and human performance. To quantify the
pharmacokinetics of TurboCBD™ will allow us to make informed recommendations of
optimum dosing in order to improve vascular health and performance throughout
healthy aging. Once we understand these processes better, the applications to
various clinical populations can then be explored. There are also many other CBD
products from Lexaria that could also be explored in due course -- the
partnership with academia and Lexaria Biosciences is an excellent means to
develop new collaborative ideas, products and positively impact society."
"Lexaria is proud to be advancing our collective knowledge of the benefits of
CBD specifically showcasing the benefits of Lexaria's unique patented delivery
technology," said Chris Bunka, CEO of Lexaria Bioscience. "Results will advance
Lexaria's ability to custom design products that increase the leading
performance our technology already offers to customers."
Additional information will be released upon completion and interpretation of
test results.
About LexariaLexaria Bioscience Corp. has developed and out-licenses its
disruptive technology that promotes healthier ingestion methods, lower overall
dosing and higher effectiveness of lipophilic active molecules. Lexaria has
multiple patents pending in over 40 countries around the world and was granted
its first patents in the USA and in Australia related to edible forms of
cannabinoids. Lexaria's technology provides increases in intestinal absorption
rates; more rapid delivery to the bloodstream; and important taste-masking
benefits, for orally administered bioactive molecules including cannabinoids,
vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other
molecules.
www.lexariabioscience.com
For regular updates, connect with Lexaria on Facebook (https://www.facebook.com/Lexaria-Corp-106280556370600/)
and Twitter (https://twitter.com/lexariacorp)
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not
historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: that
any additional stock warrants or stock options will be exercised. Such
forward-looking statements are estimates reflecting the Company's best judgment
based upon current information and involve a number of risks and uncertainties,
and there can be no assurance that other factors will not affect the accuracy of
such forward-looking statements. Factors which could cause actual results to
differ materially from those estimated by the Company include, but are not
limited to, government regulation, managing and maintaining growth, the effect
of adverse publicity, litigation, competition, the patent application and
approval process and other factors which may be identified from time to time in
the Company's public announcements and filings. There is no assurance that
existing capital is sufficient for the Company's needs or that it will be able
to raise additional capital. There is no assurance that Lexaria will
successfully complete any other contemplated or existing technology license
agreements; or that results from any studies will be favorable or in any way
support future business activities of any kind. There is no assurance that any
planned corporate activity, business venture, or initiative will be pursued, or
if pursued, will be successful. There is no assurance that any of Lexaria's
postulated uses, benefits, or advantages for the patented and patent-pending
technology will in fact be realized in any manner or in any part. No statement
herein has been evaluated by the Food and Drug Administration (FDA). Lexaria
Energy Foods, Ambarii, and ViPova™ products are not intended to diagnose, treat,
cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard
Communications Manager
(778) 796-1897
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
Source: Lexaria Bioscience Corp
Lexaria Announces Attendance
at Two Cannabis Investment Conferences and Issues Shares for Debt
KELOWNA, BC -- (Marketwired) -- Aug 29, 2017 -- Lexaria Bioscience Corp. (OTCQB:
LXRP)(CSE:
LXX.CN) (the
"Company" or "Lexaria") announces it is attending and exhibiting
at the Investorshub International Cannabis Conference in Los Angeles on
September 1-2, held at the JW Marriott downtown. Chris Bunka, CEO of Lexaria,
will be giving a presentation on the latest technology available to benefit the
cannabis industry.
On September 7-8, Lexaria is attending and exhibiting at The Institutional
Capital & Cannabis Conference (East) in Miami Beach. This conference is targeted
at high net worth investors, family offices, and institutions as an East Coast
follow up to an earlier sold-out event in California.
Meanwhile, Lexaria has received and executed a notice of conversion related to
certain convertible debt, extinguishing a
$45,000 convertible debt plus interest for 307,500 restricted common shares at
the contracted conversion price of US$0.15. Lexaria has also issued 32,433
common shares to settle US$12,000 of debt to a director, at a conversion price
of US$0.37 per share.
The securities referred to herein will not be or have not been registered under
the United States Securities Act of 1933, as amended, and may not be offered or
sold in the United States absent registration or an applicable exemption from
registration requirements.
About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive
technology that promotes healthier ingestion methods, lower overall dosing and
higher effectiveness of lipophilic active molecules. Lexaria has multiple
patents pending in over 40 countries around the world and was granted its first
patents in the USA and in Australia related to edible forms of cannabinoids.
Lexaria's technology provides increases in intestinal absorption rates; more
rapid delivery to the bloodstream; and important taste-masking benefits, for
orally administered bioactive molecules including cannabinoids, vitamins,
non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp
Chris Bunka
Chairman & CEO
(250) 765-6424
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not
historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: that
any additional stock warrants or stock options will be exercised. Such
forward-looking statements are estimates reflecting the Company's best judgment
based upon current information and involve a number of risks and uncertainties,
and there can be no assurance that other factors will not affect the accuracy of
such forward-looking statements. Factors which could cause actual results to
differ materially from those estimated by the Company include, but are not
limited to, government regulation, managing and maintaining growth, the effect
of adverse publicity, litigation, competition, the patent application and
approval process and other factors which may be identified from time to time in
the Company's public announcements and filings. There is no assurance that
existing capital is sufficient for the Company's needs or that it will be able
to raise additional capital. There is no assurance that Lexaria will
successfully complete any other contemplated or existing technology license
agreements. There is no assurance that any planned corporate activity, business
venture, or initiative will be pursued, or if pursued, will be successful. There
is no assurance that any of Lexaria's postulated uses, benefits, or advantages
for the patented and patent-pending technology will in fact be realized in any
manner or in any part. No statement herein has been evaluated by the Food and
Drug Administration (FDA). Lexaria Energy Foods and ViPova™ products are not
intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
SOURCE: Lexaria Bioscience Corp.
CEO Chris Bunka was
Interviewed on Uptick Network Discussing Company’s Positive Future Progress
KELOWNA, BC -- (Marketwired) -- Aug 10, 2017 -- Lexaria Bioscience Corp. (OTCQB:
LXRP)(CSE:
LXX.CN) (the
"Company" or "Lexaria") CEO Chris Bunka was interviewed on the
Uptick Network Stock Day Radio Show with host Everett Jolly. Mr. Bunka updates
the Uptick Network on the overall accomplishments that have presented itself in
the past 3 months. Mr. Bunka further discusses the outlook for shareholders,
their expectations for the company’s profitability and where the company is at
in this progress. R&D could open the NSAID and Nicotine markets to Lexaria and
with significant increase in corporate revenues, additional expansion is ahead.
In closing CEO, Chris Bunka states, “In the next 12 months you won’t even
recognize Lexaria. If you look at it today and look at where we are going to be
in the next 12 months… I think we are going to be an entirely different
company.”
The interview was paid by Lexaria Bioscience Corp and approved by Chris Bunka.
The distribution was sent out to the Uptick Network Stock Day Podcast, sponsors,
its affiliates and social media distribution platforms.
To listen to the interview please click here or the following link: https://upticknewswire.com/featured-interview-ceo-chris-bunka-of-lexaria-bioscience-corp-otcqb-lxrp-2
About Lexaria
Lexaria Bioscience Corp. is a biosciences company with a proprietary technology
for improved delivery of bioactive compounds. The Company's lipophilic
enhancement technology has been proven to enhance the bioavailability of orally
ingested cannabinoids, while also improving taste. This technology promotes
healthy ingestion methods, lower overall dosing and higher effectiveness in
active molecule delivery. The Company's technology is patent-protected for
cannabidiol (CBD) and all other non-psychoactive cannabinoids, and
patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids,
non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
For more information, visit http://www.LexariaEnergy.com/
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended and Section 21E of the Securities
Exchange Act of 1934, as amended. All forward-looking statements are inherently
uncertain as they are based on current expectations and assumptions concerning
future events or future performance of the company. Readers are cautioned not to
place undue reliance on these forward-looking statements, which are only
predictions and speak only as of the date hereof. In evaluating such statements,
prospective investors should review carefully various risks and uncertainties
identified in this release and matters set in the company's SEC filings. These
risks and uncertainties could cause the company's actual results to differ
materially from those indicated in the forward-looking statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard
Communications Manager
(778) 796-1897
Lexaria Bioscience Corp.
Alex Blanchard
Communications Manager
(778) 796-1897
Source: Lexaria Bioscience Corp
FDA Proposal Puts Spotlight on Big Tobacco and Industry Innovators
New York, NY – August 16, 2017 –
NetworkNewsWire.com News
Coverage: The black cloud over Big Tobacco has been swirling for
decades, but few developments have cast a bigger shadow than the U.S. Food and
Drug Administration’s recent proposal to reduce nicotine levels in cigarettes to
non-addictive levels. The new plan1, originally unveiled on July 28, is expected
to serve as a multi-year roadmap aimed at saving lives and significantly
reducing the effects of tobacco-related
diseases.
The market effects of the nicotine push have proven to be colossal, with shares
of two of the largest sellers of cigarettes in the United States suffering their
largest single-day plunge since the recession following the announcement.
Indeed, the FDA’s sweeping efforts seem to strike a distinctly adversarial tone
with the $130 billion U.S. tobacco industry2, presenting an unprecedented
opening for companies in position to cash in on the changing market.
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE:LXX.CN) as the only cannabis
biotech company that has exposure to nicotine, stands alongside industry
mainstays such as Altria Group, Inc. (NYSE: MO), Philip Morris International,
Inc. (NYSE: PM) and British American Tobacco p.l.c. (NYSE: BTI), along with
upstart 22nd Century Group, Inc. (NYSE: XXII), as the transformation of this
global industry accelerates.
The slow death of the once ubiquitous cigarette wasn’t just uncovered with the
FDA’s ruling. In fact, Big Tobacco has had its sights set on the development of
marketable alternatives to its combustible offerings for years. A quick visit to
Philip Morris’ website demonstrates these efforts, as the tagline “Designing a
Smoke-Free Future” is placed front-and-center for all to see. As a reminder,
Philip Morris is the global cigarette giant behind Marlboro and six of the
world’s top 15 international brands, and its tobacco products are currently sold
in over 180 countries outside the U.S.
Though still in their relative infancy, smoke-free cigarette alternatives have
already proven to be highly marketable as cigarettes and similar products have
faced increasing regulations and slumping sales. Per a report3 from the Centers
for Disease Control and Prevention, roughly 9 million adult consumers, or 3.7
percent of American adults, used tobacco-free electronic cigarettes or vapor
products on a regular basis in 2014. These products typically serve as a
delivery method for nicotine, and the National Institute on Drug Abuse4 reports
that they are often used to lower nicotine cravings for those who are trying to
quit smoking. However, as the Institute notes, there is currently no conclusive
scientific evidence on the effectiveness of e-cigarettes for long-term smoking
cessation, and, perhaps more importantly, the safety characteristics of these
devices haven’t been thoroughly evaluated in independent scientific studies.
A dearth of safe alternatives and an increasingly regulated tobacco industry
combine to create a large and rapidly expanding market for smoking cessation
solutions. According to a 2016 report5 by Grand View Research, Inc., the global
smoking cessation and nicotine de-addiction market is expected to reach over
$21.8 billion by 2024. As Grand View reports,
“The launch of… improved and innovative nicotine replacement therapy products is
to serve as a high impact rendering driver for the growth of the smoking
cessation and nicotine de-addiction market.” Staring at a fertile market that’s
concentrated on driving innovation,
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE:LXX.CN), with its patented
lipid-delivery technology, could prove to be a long-term player offering vast
positive community health benefits and considerable upside, particularly for
early investors.
Lexaria Bioscience’s intellectual property portfolio features a collection of
advancements focused on improving the delivery and absorption of targeted
molecules – such as nicotine - to the human body. Notably, the company maintains
a patented method by which it is able to infuse a cocktail of molecules that are
otherwise difficult for the body to absorb within other ingredients at a
molecular level. As Lexaria’s website outlines, the company’s platform allows
for the infusion of beneficial hemp oil ingredients into easily-absorbed lipids,
greatly increasing the efficiency of absorption. Currently implemented in the
production of two distinct consumer product brands including ViPova™ and Lexaria
Energy, this technology has proven to be a potential game changer in the
cannabinoid-based pharmaceuticals market, an industry that’s on course to grow
to $50 billion by 2029, per data aggregated by Statista6.
An equally promising application of this technology relates to the delivery of
nicotine, which is also referenced in Lexaria’s lipid-based delivery patent. The
company’s proprietary platform allows for the infusion of nicotine molecules
within a wide range of edible food ingredients or typical capsule formats,
effectively opening the door for the creation of a new product category
targeting the high-demand smoking cessation market. Edible or encapsulated forms
of nicotine delivery have traditionally failed due to challenges that Lexaria’s
new technology may overcome. As the company notes, most of the adverse health
outcomes associated with nicotine consumption are due to problematic delivery
methods, such as cigarettes and other combustible products. As such, the
development of nicotine-infused edible products that remove those dangerous side
effects could greatly improve upon the safety profile of most currently-marketed
options.
Though promising, Lexaria’s patented molecular delivery technology remains in
its early stages. The company is currently investigating the best methods of
maximizing on the platform’s market potential. As part of these efforts, Lexaria
is also examining the feasibility of in-vitro and in vivo laboratory tests of
its technology in order to generate real data regarding the bioavailability of
nicotine with and without its protective technology. Combined with potential
market indications in the delivery of non-steroidal anti-inflammatories (NSAIDs)
and vitamins, markets valued at $5.4 billion and $68 billion respectively,
Lexaria’s lipid-delivery technology makes the company an intriguing option for
investors with a finger on the pulse of the evolving tobacco industry.
While Lexaria focuses on the development of new delivery technologies for
nicotine, much of Big Tobacco has already turned its attention toward the
development of reduced-risk alternatives to combustible products. On its
website, Altria Group, Inc. (NYSE: MO), parent company of Philip Morris USA and
cigar-maker John Middleton Co., among others, notes that its goals are to
develop lower-risk tobacco products for adult consumers, support programs that
help reduce underage tobacco use and provide access to expert quitting
information for those who have decided to quit. For Altria and many other
tobacco industry leaders, much of the focus remains on electronic cigarettes and
e-vapor products.
This interest in the electronic cigarette market has seen a lot of early
success, though, as noted in an April 2016 report7 from the Royal College of
Physicians, “[I]t is not possible to estimate the long-term health risk
associated with e-cigarettes precisely.” In 2015, sales of e-cigarettes totaled
$2.88 billion, according to Statistic Brain8, up from just $20 million in 2008.
A former operating company of Altria Group, Philip Morris International, Inc.
(NYSE: PM) was spun off in 2008 in an effort to better pursue sales growth in
emerging markets. Philip Morris’ most extensive project in the
cigarette-alternative space is iQOS (I-Quit-Ordinary-Smoking), which it
originally announced in 2014 and currently markets under the Marlboro and
Parliament brands. Rather than burning tobacco, the iQOS employs heat to
generate a tobacco-based aerosol containing nicotine. As of the end of 2016,
Philip Morris’ iQOS was available in over 20 countries, with the company teaming
with Altria Group to bring the product to the U.S. in the coming months.
Although iQOS and similar heat-not-burn tobacco products present some benefits
over cigarettes, such as leaving less smell and odor on clothing, independent
research is not currently available to support claims of lowered risk or health
benefits, according to the World Health Organization.
British American Tobacco p.l.c. (NYSE: BTI) categorizes its efforts outside of
the traditional tobacco space as “Next Generation Products,” a classification
that includes an assortment of alternative tobacco and nicotine products aimed
at reducing the risks associated with smoking conventional cigarettes. Per its
website, British American Tobacco, over the past five years, has invested more
than $1 billion in building its Next Generation Products business. In 2013, it
became the first international tobacco company to launch an e-cigarette product
in the UK. Since launching its Vype product line, British American Tobacco has
introduced products such as the Vype ePen, eTank and eBox, as well as iFuse and
glo, two tobacco heating products similar to those offered by Philip Morris.
As with many of its competitors, 22nd Century Group, Inc. (NYSE: XXII) is
focused on reducing the harm caused by smoking, as is communicated through a
tagline on its website. Unlike many of its competitors, however, 22nd Century’s
products are taking direct aim at the FDA’s latest proposal. As noted in a
recent Bloomberg article9, this relatively obscure biotechnology company in
western New York grows tobacco plants with just three percent of the nicotine
found in typical tobacco plants. Using these plants, the company creates Very
Low Nicotine cigarettes that are expected to go through the FDA-approval process
as a prescription smoking cessation aid. This innovative approach which, like
that of Lexaria Bioscience Corp., goes against the grain in an industry filled
to the brim with e-cigarettes and vaping products, has already started to pay
off for 22nd Century investors. While Big Tobacco stocks plunged following the
FDA’s nicotine announcement, 22nd Century’s shares were up 70 percent for the
week ended August 4, including a 25 percent increase on Friday that marked its
biggest one-day spike since March 2015.
Where there’s smoke, there’s fire, and Big Tobacco’s industry-wide commitment to
developing pioneering devices in the face of increasingly stringent FDA
regulations is impossible to overlook. Still, electronic cigarette alternatives
and heat-not-burn tobacco products could be half measures in a market that’s
primed for a major overhaul. Look for true innovators like Lexaria Bioscience
Corp., with its patented lipid-based delivery technology, to develop a foothold
as the next iteration of the global $600 billion tobacco industry begins to take
shape.
NNW Editorial Sources:
1. FDA http://nnw.fm/2SUkk
2. Bloomberg http://nnw.fm/qQZ00
3. CDC http://nnw.fm/7mXiJ
4. NIDA http://nnw.fm/bM5vN
5. Grandview Research http://nnw.fm/Ytnr1
6. Statista http://nnw.fm/D7L1i
7. Royal College of Physicians http://nnw.fm/kfD16
8. Statistic Brain http://nnw.fm/j4JD4
9. Bloomberg http://nnw.fm/bvH0s
For more information on Lexaria Bioscience please visit: Lexaria Bioscience
Corp. (CSE: LXX) (OTCQB: LXRP)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our
news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize
corporate news and information, (3) enhanced press release services, (4) social
media distribution and optimization services, and (5) a full array of corporate
communication solutions. As a multifaceted financial news and content
distribution company with an extensive team of contributing journalists and
writers, NNW is uniquely positioned to best serve private and public companies
that desire to reach a wide audience of investors, consumers, journalists and
the general public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting through the
overload of information in today’s market, NNW brings its clients unparalleled
visibility, recognition and brand awareness. NNW is where news, content and
information converge.
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website
applicable to all content provided by NNW, wherever published or re-published:
http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set
forth above. References to any issuer other than the profiled issuer are
intended solely to identify industry participants and do not constitute an
endorsement of any issuer and do not constitute a comparison to the profiled
issuer. FN Media Group (FNM) is a third-party publisher and news dissemination
service provider, which disseminates electronic information through multiple
online media channels. FNM is NOT affiliated with NNW or any company mentioned
herein. The commentary, views and opinions expressed in this release by NNW are
solely those of NNW and are not shared by and do not reflect in any manner the
views or opinions of FNM. Readers of this Article and content agree that they
cannot and will not seek to hold liable NNW and FNM for any investment decisions
by their readers or subscribers. NNW and FNM and their respective affiliated
companies are a news dissemination and financial marketing solutions provider
and are NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy any
security.
The Article and content related to the profiled company represent the personal
and subjective views of the Author, and are subject to change at any time
without notice. The information provided in the Article and the content has been
obtained from sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all such
information. None of the Author, NNW, FNM, or any of their respective
affiliates, guarantee the accuracy or completeness of any such information. This
Article and content are not, and should not be regarded as investment advice or
as a recommendation regarding any particular security or course of action;
readers are strongly urged to speak with their own investment advisor and review
all of the profiled issuer's filings made with the Securities and Exchange
Commission before making any investment decisions and should understand the
risks associated with an investment in the profiled issuer's securities,
including, but not limited to, the complete loss of your investment.
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and NNW and FNM undertake no obligation to update
such statements.
Media Contact e-mail: FN Media Group, LLC - editor@financialnewsmedia.com
(954)345-0611
News Source: NetworkNewsWire
Lexaria Bioscience Corp.
Engages NetworkNewsWire for Corporate Communications Solutions
KELOWNA, BC -- (Marketwired) -- Aug 2, 2017 -- Lexaria Bioscience Corp. (OTCQB:
LXRP)(CSE:
LXX.CN) (the
"Company" or "Lexaria") an innovative company licensing
proprietary technology for delivery of bioactive compounds including
cannabinoids, announces that it has engaged the corporate communications
expertise of NetworkNewsWire ("NNW").
"We are excited to be on the cutting-edge of bioscience, developing better ways
to deliver health-enhancing cannabinoids to the body," says Lexaria Bioscience
CEO and chairman of the board Chris Bunka. "As we continue to fulfil our mission
of improving our customers' quality of life through our patented process, we
expect our new association with NetworkNewsWire to enhance our initiatives to
keep shareholders and potential investors aware of our progress and potential."
NNW is a multifaceted financial news and publishing company that delivers a new
generation of social communication
solutions, news aggregation and syndication, and enhanced news release services.
NNW's strategies help public and private organizations find their voice and
build market visibility. As part of the Client-Partner relationship with Lexaria
Bioscience, NNW will leverage its investor-based distribution network of over
5,000 key syndication outlets, various newsletters, social media channels,
blogs, and other outreach tools to generate greater brand awareness for the
Company.
"Lexaria Bioscience is headed in an exciting direction with proprietary
technology for improving taste and delivery of bioactive compounds, and is a
first mover in the plant-to-bloodstream niche," states Sherri Franklin, director
of Content Marketing for NNW. "We look forward to working with Chris and the
team at Lexaria to develop a communications strategy that best tells their story
to the investment community."
About Lexaria
Lexaria Bioscience Corp. is a biosciences company with a proprietary technology
for improved delivery of bioactive compounds. The Company's lipophilic
enhancement technology has been proven to enhance the bioavailability of orally
ingested cannabinoids, while also improving taste. This technology promotes
healthy ingestion methods, lower overall dosing and higher effectiveness in
active molecule delivery. The Company's technology is patent-protected for
cannabidiol (CBD) and all other non-psychoactive cannabinoids, and
patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids,
non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
For more information, visit http://www.LexariaEnergy.com/
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides to users (1)
access to our news aggregation and syndication servers, (2) enhanced press
release services, and (3) a full array of social communication solutions. As a
multifaceted financial news and content distribution company with an extensive
team of contributing journalists and writers, NNW is uniquely positioned to best
serve private and public companies that desire to reach a wide audience of
investors, consumers, journalists and the general public. NNW has an
ever-growing distribution network of more than 5,000 key syndication outlets
across the country. By cutting through the overload of information in today's
market, NNW brings its clients unparalleled visibility, recognition and brand
awareness. NNW is where news, content and information converge.
For more information, visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website
applicable to all content provided by NNW, wherever published or re-published:
http://NNW.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended and Section 21E of the Securities
Exchange Act of 1934, as amended. All forward-looking statements are inherently
uncertain as they are based on current expectations and assumptions concerning
future events or future performance of the company. Readers are cautioned not to
place undue reliance on these forward-looking statements, which are only
predictions and speak only as of the date hereof. In evaluating such statements,
prospective investors should review carefully various risks and uncertainties
identified in this release and matters set in the company's SEC filings. These
risks and uncertainties could cause the company's actual results to differ
materially from those indicated in the forward-looking statements.
NNW Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Email Contact
Source: Lexaria Bioscience Corp.
Biotech Players Lead the Growth
Charge in the Legal Cannabis Market
New York, NY – July 27, 2017 –
NetworkNewsWire.com News
Coverage: The backbone of medical advancement is biotechnology, an
industry wrought with the incredible potential of novel drug R&D, but vulnerable
to the risk of stringent regulatory approval processes. Within this volatile
market, however, is the cannabis-biotech sub-sector – a market
flourishing
with opportunity, innovation, and deep roots of medical possibilities. Fueled by
an increasing volume of supportive research, cannabis-based biotech companies
are addressing large markets of unmet medical need while rising to meet global
demand of epic proportion. Included among several companies in the
cannabis-biotech sub-sector is
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX.CN), a company emerging
as a recognizable name within a space occupied by companies like GW
Pharmaceuticals PLC (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE),
Insys Therapeutics, Inc. (NASDAQ: INSY) and Axim Biotechnologies Inc. (OTC: AXIM).
Because the cannabis-biotech sub-sector remains in relative infancy, it is full
of uncharted territory and prospects as companies aggressively explore the
medicinal potential of marijuana and the plant’s compounds and applications.
Food bioscience company
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX.CN), for instance,
enjoys a unique position in this sub-sector. As the only publicly traded company
with a cannabis-based intellectual portfolio that includes NSAIDs, nicotine and
vitamins, Lexaria has multiple patents pending in over 40 countries, and it
recently received its first patents in the U.S. and Australia relating to edible
forms of cannabinoids (http://nnw.fm/e8LvY).
At the center of these patents is the company’s proprietary technology, which
improves the delivery of bioactive compounds, primarily cannabinoids, into the
human body. While cannabinoids tout great potential for medical treatment, the
compounds are poorly absorbed by the gastrointestinal tract. As a result, users
frequently turn to alternative administration methods, like smoking, for
enhanced effectiveness. Lexaria’s lipophilic enhancement technology, however,
demonstrates the ability to boost bioavailability of orally-ingested
cannabinoids while at the same time masking their “unusual” taste. This
technology is patent-protected for cannabidiol (CBD) and all other
non-psychoactive cannabinoids. Other patents are also pending for
tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
In collaboration with the National Research Council of Canada (“NRC”) (http://nnw.fm/fdG8Z),
Lexaria has commenced lab work to study and optimize the application of its
technology toward enabling the delivery of lipophilic active agents within
foods, beverages, capsules and other ingestible formats. Practical applications
of this collaboration could include expansion of Lexaria's IP portfolio and the
possibility of new commercial arrangements. Lexaria currently has two distinct
consumer brands that utilize this game-changing technology of infusing hemp oil
inside the lipids in foods:
ViPova™ and Lexaria Energy.
Introduced in 2015, the ViPova product line began with a Chinese black tea
containing hemp oil infused into dried, evaporated nonfat milk. The following
year, Lexaria took advantage of the broader beverage market, and ViPova’s
product line was expanded to include coffee and hot chocolate. The company sells
its ViPova product directly online to consumers.
Lexaria Energy products also utilize the company’s patented infusion technology
to deliver federally legal hemp oil ingredients inside nutritious and tasty
formulations that are free of the bitter taste typically associated with hemp.
Products in this line include the Lexaria Energy Bar, a hemp oil-infused protein
bar. Other nutritious products are in development for the Lexaria Energy line,
with a focus on ensuring responsible production techniques and gluten-free
formulations.
Lexaria also licenses its technology to third-party partners, making royalties
an integral part of its overall business strategy and revenue potential as it
pursues opportunities to broaden and strengthen its IP portfolio. Because
Lexaria's technology relies on a delivery methodology - and not just a single
drug or molecule - even cannabis giants like GW Pharmaceuticals PLC (NASDAQ:
GWPH) might discover Lexaria's technology as an effective way to deliver its
drug.
GW Pharmaceuticals has become a world leader in developing plant-derived
cannabinoid therapeutics by leveraging its established drug discovery and
development processes, extensive intellectual property portfolio, and regulatory
and manufacturing expertise. The company’s research delves into the potential
therapeutic applications of cannabinoids, and GW has evaluated the pharmacology
of various cannabinoids across a broad array of disease areas. GW’s focus is
chiefly on central nervous system disorders, including epilepsy. The company’s
lead product candidate, Epidiolex, is a liquid formulation of pure plant-derived
CBD and is in development to treat various rare childhood-onset epilepsy
disorders. GW has also commercialized Sativex, the world’s very first
plant-derived cannabinoid prescription drug, which has been approved in 29
countries outside the U.S. for the treatment of multiple sclerosis-related
spasticity. GW’s pipeline of other cannabinoid product candidates includes
compounds in development for treating epilepsy, glioma and schizophrenia.
Another biotech standout in the cannabis market is clinical-stage pharmaceutical
company Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE). Zynerba is focused on the
development of innovative transdermal synthetic cannabinoid treatment options
for patients with high unmet medical needs. The company’s development pipeline
includes two lead product candidates that are being evaluated in five
therapeutic indications: ZYN002 and ZYN001. Currently in phase 2 clinical
development for refractory epilepsy, osteoarthritis of the knee and Fragile X
syndrome, ZYN002 is the first and only synthetic form of CBD and has been
formulated as a patent-protected permeation-enhanced gel for transdermal
delivery into the circulatory system. ZYN001 is a THC pro-drug that enables
transdermal delivery through the skin and into the circulatory system via a
patch. A phase 1 clinical program for fibromyalgia and peripheral neuropathic
pain was initiated by Zynerba in the first half of 2017.
Specialty pharmaceutical company Insys Therapeutics, Inc. (NASDAQ: INSY) is
focused on developing and commercializing innovative drugs and novel drug
delivery systems for therapeutic molecules with the end goal of improving
quality of life for patients. Insys uses proprietary sublingual spray technology
along with its pharmaceutical cannabinoid development capabilities to address
the clinical inadequacies of existing commercial products. In May 2017, Insys
Therapeutics received FDA approval for the final product label of its Syndros (dronabinol)
oral solution, marking the last regulatory step needed before the official
launch of the product, which is planned to take place sometime in August 2017.
Syndros is a liquid formulation of the pharmaceutical cannabinoid dronabinol and
has been approved for use in the treatment of weight loss-related anorexia in
AIDS patients and nausea and vomiting in chemotherapy patients who are
unresponsive to conventional antiemetic treatments. Insys is additionally at the
phase 2 clinical development stage for a cannabidiol treatment to address severe
pediatric epilepsies.
Biotechnology company Axim Biotechnologies Inc. (OTCQB: AXIM) is a leader in
cannabinoid R&D and is striving to set the green standard for cannabinoid
bioscience. The company’s most advanced program is its phase 2 clinical trial of
CanChew Plus chewing gum to treat irritable bowel syndrome. The company is
similarly using a chewing gum-based approach for the treatment of pain, multiple
sclerosis spasticity and other indications. CanChew Gum is the world’s first
patented, functional chewing gum that is derived from CBD-rich industrial hemp,
and it is legal in all 50 states. Axim is additionally conducting research into
the use of molecularly-modified cannabinoids as neuroprotectants, as well as the
use of industrial hemp-derived formulations of cannabigerol (CBG) for
dermatological applications. AXIM is further conducting trials or has products
in development targeting a large number of indications, including ADHD, smoking
cessation, ulcerative colitis, Crohn’s disease, drug-related psychosis,
psoriasis, atopic dermatitis and more. The company is also in the process of
developing a unique extraction and freeze-drying technology for producing
molecularly/genetically-controlled pharma-grade cannabinoids extracted from
industrial hemp.
For biotech investors looking at the legal cannabis sector and interested in
potentially taking part of the growth in the broader marijuana industry, the
companies described above are all worth keeping on your investment radar. Stay
tuned to NetworkNewsWire for more public information on investment opportunities
and on Lexaria Bioscience.
For more information on Lexaria Bioscience, please visit:
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX.CN)
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our
news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize
corporate news and information, (3) enhanced press release services, (4) social
media distribution and optimization services, and (5) a full array of corporate
communication solutions. As a multifaceted financial news and content
distribution company with an extensive team of contributing journalists and
writers, NNW is uniquely positioned to best serve private and public companies
that desire to reach a wide audience of investors, consumers, journalists and
the general public. NNW has an ever-growing distribution network of more than
5,000 key syndication outlets across the country. By cutting through the
overload of information in today’s market, NNW brings its clients unparalleled
visibility, recognition and brand awareness. NNW is where news, content and
information converge.
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website
applicable to all content provided by NNW, wherever published or re-published:
http://NNW.fm/Disclaimer
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set
forth above. References to any issuer other than the profiled issuer are
intended solely to identify industry participants and do not constitute an
endorsement of any issuer and do not constitute a comparison to the profiled
issuer. FN Media Group (FNM) is a third-party publisher and news dissemination
service provider, which disseminates electronic information through multiple
online media channels. FNM is NOT affiliated with NNW or any company mentioned
herein. The commentary, views and opinions expressed in this release by NNW are
solely those of NNW and are not shared by and do not reflect in any manner the
views or opinions of FNM. Readers of this Article and content agree that they
cannot and will not seek to hold liable NNW and FNM for any investment decisions
by their readers or subscribers. NNW and FNM and their respective affiliated
companies are a news dissemination and financial marketing solutions provider
and are NOT registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy any
security.
The Article and content related to the profiled company represent the personal
and subjective views of the Author, and are subject to change at any time
without notice. The information provided in the Article and the content has been
obtained from sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all such
information. None of the Author, NNW, FNM, or any of their respective
affiliates, guarantee the accuracy or completeness of any such information. This
Article and content are not, and should not be regarded as investment advice or
as a recommendation regarding any particular security or course of action;
readers are strongly urged to speak with their own investment advisor and review
all of the profiled issuer's filings made with the Securities and Exchange
Commission before making any investment decisions and should understand the
risks associated with an investment in the profiled issuer's securities,
including, but not limited to, the complete loss of your investment.
NNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and NNW and FNM undertake no obligation to update
such statements.
Media Contact e-mail: FN Media Group, LLC - editor@financialnewsmedia.com
(954)345-0611
News Source: NetworkNewsWire
National Research Council and
Lexaria Bioscience Commence Laboratory Work
KELOWNA, BC -- (Marketwired) -- 07/20/17 -- Lexaria Bioscience Corp. (OTCQB:
LXRP)(CSE:
LXX.CN) (the
"Company" or "Lexaria") announces the start of laboratory work under its
collaborative research program with the National Research Council of Canada
("NRC"), following the completion of preparation initiatives announced on March
14, 2017.
As earlier reported, several studies will be initiated in the coming months
designed to optimize Lexaria's patented technology enabling delivery of
lipophilic active agents within foods, beverages, capsules and other ingestible
formats. These studies will investigate lipophilic active agent classes
including cannabinoids, vitamins, NSAIDs, and nicotine.
Advanced analytical techniques including mass spectrometry and nuclear magnetic
resonance testing will be used to evaluate the chemical nature of the molecular
association that Lexaria's technology is believed to form between lipophilic
active agents and the flavor and delivery enabling fatty acid agents that are
integral to Lexaria's
formulation methodologies. Practical applications of this work could include
further broadening or strengthening of Lexaria's intellectual property portfolio
and may also provide the foundation for new commercial arrangements.
"We are delighted to have commenced formulation development and characterization
work together with the NRC," stated John Docherty, president of Lexaria
Bioscience. "The NRC team has extensive knowledge and experience in the field of
lipid based delivery systems relating to pharmaceutical products, natural health
products and functional foods. This collaboration will significantly assist
Lexaria in further developing and characterizing its IP portfolio."
Additional information will be released upon completion and interpretation of
test results.
About LexariaLexaria Bioscience Corp. has developed and out-licenses its
disruptive technology that promotes healthier ingestion methods, lower overall
dosing and higher effectiveness of lipophilic active molecules. Lexaria has
multiple patents pending in over 40 countries around the world and was granted
its first patents in the USA and in Australia related to edible forms of
cannabinoids. Lexaria's technology provides increases in intestinal absorption
rates; more rapid delivery to the bloodstream; and important taste-masking
benefits, for orally administered bioactive molecules including cannabinoids,
vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other
molecules.
www.lexariabioscience.com
For regular updates, connect with Lexaria on Facebook (https://www.facebook.com/Lexaria-Corp-106280556370600/)
and Twitter (https://twitter.com/lexariacorp)
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not
historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: that
any additional stock warrants or stock options will be exercised. Such
forward-looking statements are estimates reflecting the Company's best judgment
based upon current information and involve a number of risks and uncertainties,
and there can be no assurance that other factors will not affect the accuracy of
such forward-looking statements. Factors which could cause actual results to
differ materially from those estimated by the Company include, but are not
limited to, government regulation, managing and maintaining growth, the effect
of adverse publicity, litigation, competition, the patent application and
approval process and other factors which may be identified from time to time in
the Company's public announcements and filings. There is no assurance that
existing capital is sufficient for the Company's needs or that it will be able
to raise additional capital. There is no assurance that Lexaria will
successfully complete any other contemplated or existing technology license
agreements; or that results from any studies will be favorable or in any way
support future business activities of any kind. There is no assurance that any
planned corporate activity, business venture, or initiative will be pursued, or
if pursued, will be successful. There is no assurance that any of Lexaria's
postulated uses, benefits, or advantages for the patented and patent-pending
technology will in fact be realized in any manner or in any part. No statement
herein has been evaluated by the Food and Drug Administration (FDA). Lexaria
Energy Foods, Ambarii, and ViPova™ products are not intended to diagnose, treat,
cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard
Communications Manager
(778) 796-1897
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
Source: Lexaria Bioscience Corp
-------------------------------------------------------------------
About Lexaria Bioscience Corp.:
Lexaria Bioscience Corp. is a food biosciences company with a proprietary
technology for improved delivery of bioactive compounds. The Company’s
lipophilic enhancement technology has been shown to enhance the bioavailability
of orally ingested cannabinoids, while also masking taste.
Cannabinoids are poorly absorbed by the body’s gastrointestinal tract and
consumers often default to alternate routes of administration like smoking to
achieve higher effectiveness.
The Company’s technology is patent-protected for cannabidiol (CBD) and all other
non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol
(THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs),
nicotine and other molecules.
Lexaria’s propiertary technology delivers the following advantages for
cannabinoid edibles:
- Masks taste – eliminates the strong tastes in cannabinoid edibles, enabling
zero-sugar formats.
- Reduces time of onset – effects are felt within 15-20 min vs. 60-120 min.
- Increases bio-absorption – by 5 – 10X, to equate or excel that of inhalation.
Business Model:
- Out-license (royalty) the technology to third-party partners / distributors.
As of early 2017 Lexaria has six deals signed/pending (2 definitive agreements,
4 LOI/MOU’s pending).
- Product Sales – Lexaria sells hemp oil (containing cannabidiol) products.
Lexaria’s branded protein energy bars are excellent for energy, fiber and
protein. ViPova™ branded premium teas deliver full spectrum hemp oil in several
flavors of delicious black and herbal teas.
Patent Portfolio – Lexaria has 12 patent applications filed in the US,
International (under the Patent Cooperation Treaty), and national filings in 42
countries. Patents include both method and composition of matter claims. The
patents name a broad range of bioactive substances that can be formulated and
delivered using Lexaria’s technology. First patent issued by USPTO, Oct 25,
2016:
“Cannabinoid Infused Food and Beverage Compositions and Methods of Use Thereof”.
Additional patent issuances are expected to follow, including THC.
Everything we do has common elements: products and ideas that bring you comfort.
We use patented technology but we also work with Mother Nature. Brought
together, our goal is to help you achieve HARMONY in your very special life.
Food Products
Lexaria has two distinct consumer product brands: ViPovaTM and Lexaria Energy.
Both brands use patented technology to infuse hemp oil ingredients within lipids
in popular foods. Other companies selling hemp Seed oil products and hemp seed
oil drops usually just mix hemp oil with other ingredients and sell you the
resulting product. That is NOT what we do!
We actually have a patented method by which we infuse our organically sourced
high purity hemp oil INSIDE the molecules of other ingredients. We work with
lipids because the human endocannabinoid system is itself lipid based. We
believe this is a more efficient way of delivering hemp oil to your body and
that a little hemp seed oil within one of our products might be similar to a LOT
of hemp oil ingested without our proprietary technology.
VIPOVATM
We introduced ViPovaTM black tea infused with hemp oil in January, 2015. This is
a delicious Chinese black tea from the province of Yunnan, and is hemp
oil-infused within dried evaporated non-fat milk. We delivered several flavors
and varieties, including herbal decaf versions, and sell VipovaTM teas in
convenient consumer package sizes just like you would find in the grocery store.
ViPovaTM tea is available for sale today at www.vipova.com and ships nationwide.
We envision ViPovaTM to be more than just tea, however. Our vision is that
ViPovaTM will represent the true “coffee-house” experience: various types of
coffees, teas, and related goods. So, in 2016 we launched VipovaTM coffee and
also hot chocolate: and for those who are used to “unusual” tasting hemp oil
cannabinoid products, we challenge you to detect it after our patented
technology has been applied.
LEXARIA ENERGY PRODUCTS
You’re a busy, active person. Personal fitness is important to you – and so is
eating right. You love to play tennis – or golf – or go cycling – or you
exercise regularly. Life is busy and you don’t always have time to gather all
the ingredients you know you need to cook a good meal. Lexaria Energy is for
you!
Lexaria Energy products use our patented technology to efficiently deliver hemp
oil ingredients to you in nutritious and delicious formulations without making
compromises. You should be able to eat gluten-free without loads of added sugar:
we do that for you. You should be able to enjoy important quantities of protein
without feeling that you’ve just bitten into sawdust: we do that for you too.
And you should be able to enjoy the many benefits of hemp oil-based ingredients
without having to put up with a bitter taste: and we do that for you too!
First, we produce and sell edible consumer products infused with hemp oil that
are federally legal. Through our subsidiary company we launched the ViPovaTM
brand with a delicious hemp oil-infused black tea. Through our Lexaria Energy
brand we launched the Lexaria Energy Bar – a hemp oil-infused protein bar that
just might be the most delicious food you’ve ever eaten!
People who are active and on-the-go don’t always have time to sit down and enjoy
a nutritious, balanced meal. But just because you are busy doesn’t mean you have
to resort to candy bars and donuts! Lexaria Energy is working to deliver a line
of food products that are nutritious, responsibly produced, often gluten-free,
and always infused with hemp oil so that YOU don’t have to compromise between
convenience and healthy eating.
Everything we do has common elements: products and ideas that bring you comfort.
We use patented technology but we also work with Mother Nature. Brought
together, our goal is to help you achieve HARMONY in your very special life.
Intellectual Property
We live in an age where technology touches our lives constantly. When it works
well we don’t notice the tech – we only notice the benefits. Most of us have
forgotten that anti-lock brakes on our cars used to be “hi-tech”. Or that
“wireless internet” was once considered almost a miracle.
We know that delivering balanced nutrition in a single package to the human body
can be challenging. Lexaria has already taken a giant first step in a process we
believe makes us unique in the entire marketplace.
We actually have a patented method by which we infuse the healthy cocktail of
molecules in our organically sourced hemp oil INSIDE the molecules of other
ingredients. We work with lipids because the human endocannabinoid system is
itself lipid based. We believe this is a more efficient way of delivering hemp
oil ingredients to your body. Said another way, a little hemp oil within one of
our products might be similar to a LOT of hemp oil ingested without our
proprietary technology!
Why does it matter?
Raw hemp oil can taste pretty strong. But our process places the active
ingredients inside of lipids (fats and fatty acids), and as a result our
products simply taste good – many customers tell us they are the best tasting
hemp oil products they have ever tried!
Lipids are also absorbed very efficiently by the human digestive system, so we
theorize that the cocktail of hemp terpines we pack inside those lipids are more
bioavailable to your body than if they were not encased in the lipid.
The human endocannabinoid system is itself a lipid-based signalling system
working between synapses throughout many areas of your body. We think it makes
sense to deliver hemp oil to you in a lipid-based delivery system.
So you have to ask yourself: if you are going to the trouble and expense of
making sure you are ingesting hemp oil, doesn’t it make sense to be sure you are
ingesting it in a manner that is as efficient and complete as possible?
But we are not stopping there: Lexaria is investigating and budgeting research
and development dollars on additional related methods and techniques as we
continually strive to find the most efficient methods possible – the highest
bioavailability – of delivering active ingredients to you. So we are continually
discussing methods of enhancing the technology we have already developed. If we
can find ways to make it better, we will.
And we are investigating other technology related to this same concept of
delivering active ingredients to you more efficiently than other known methods.
It makes sense to ensure that the things you are eating are being delivered to
your body as effectively as possible, with the comfort of good taste and the
avoidance of stomach upset.
For competitive reasons we cannot disclose exactly in which directions all our
theories are pointing. But we can say that we have several ideas we are excited
about and are pursuing! These ideas will try to advance the understanding of the
fascinating hemp oil molecules and how they interact within the human body.
There are already public companies concentrating on the adaptation of these
molecules for various drugs in development or, in some areas of the world,
already in medical use. Although we are not pursuing drug based therapies we
remain convinced that there are advantageous methods of delivering hemp oil
molecules to the body in wholesome, nutritious foods that are superior to Mother
Nature’s original packaging.
Patents
We have filed a number of patents with the US Patent Office to protect our
intellectual property.
We also filed an International patent application under the Patent Cooperation
Treaty (PCT) procedure, in June 2015. Under the PCT, Lexaria has the ability to
pursue patent applications of its core technology in up to 148 countries in such
major markets as China, India, Japan, the US, the EU, and the UK, among others.
These patent applications for lipid-based delivery mechanisms cover but are not
limited to molecules such as THC, CBD, Nicotine, ASA, Ibruprofen, and Vitamin E.
Nicotine and Our Technology
Once we realized that our technology opened the door to a methodology that could
lead to reduced cannabis smoking in favor of cannabinoid ingestibles, we started
asking more questions.
We wondered if our technology might have applications to other molecules that
are in wide use, and we wondered if we could offer any improvements to current
delivery methods. We learned that Nicotine is such a molecule.
More than 99% of all nicotine that is consumed worldwide is delivered through
smoking cigarettes. Approximately 6,000,000 deaths per year, worldwide, are
attributed primarily to the delivery of nicotine through the act of smoking
according to the Centers for Disease Control and Prevention, which also
estimates that over $170 billion per year is spent just in the USA on direct
medical care costs for adult smokers. 69% of U.S. adult smokers want to quit
smoking and 43% of US adult smokers have attempted to quit in any twelve month
period.
Worldwide, retail cigarette sales were worth $722 billion in 2013, with over 5.7
trillion cigarettes sold to more than 1 billion smokers.
RELEVANCE: Lexaria postulates that delivery of nicotine to satisfy current
demand, utilizing our patented lipid-delivery technology in common food groups,
could shift demand from smoking cigarettes to alternative nicotine-based food
products. Since most of the adverse health outcomes of nicotine consumption are
associated with the delivery method and only to a lesser degree to the actual
ingestion of nicotine, there could be a vast positive community health outcome
through the reduction in smoking cigarettes. Additional research and regulatory
compliant investigations would need to be conducted before otherwise healthy
foods such as tea, coffee or energy bar snacks containing nicotine could be
introduced. Nicotine is a named molecule in the latest Lexaria patent
applications.
These are early days for Lexaria’s technological applications. We do not have
any current products under development in the space of nicotine delivery with
our technology, but we are investigating the best methods of making this
available to the marketplace. We are also examining whether we could design and
execute a series of in-vitro lab tests to begin generating real data as to the
bioavailability of nicotine with and without our protective technology.
Non-Steriodal Anti-Inflammatories and Our Technology
Nicotine wasn’t the only molecule that we were curious about with respect to our
lipid delivery technology. We knew that the number-one primary reason people
were prescribed medical marijuana was for the management of pain. Naturally we
thought about pain relief options.
Opioids are pain relief drugs such as morphine, oxycodone, fentanyl and more.
Although effective pain killers, they have a number of significant side effects
such as addiction, sedation, respiratory depression, hormone imbalance and more.
Other pain killers are not as effective, but we wondered if there was a way to
bridge the gap between Opioids and NSAIDs.
We wondered if less powerful pain killers such as ibuprofen, asa and
acetaminophen might be somewhat “empowered” if they had a more effective
delivery mechanism. Today we do not know the answer, but by patenting our
technology with regards to the NSAIDs, we hope to have protected our
shareholders’ value.
Non-steroidal Anti-Inflammatories are the second-largest category of pain
management treatment options in the world. The global pain management market was
estimated at $22 billion in 2011, with $5.4 billion of this market being served
by NSAID’s. The U.S. makes up over one-half of the global market. The opiods
market (such as morphine) form the largest single pain management sector but are
known to be associated with serious dependence and tolerance issues.
Some of the most commonly known NSAIDs are ASA (Aspirin), Ibruprofen (Advil,
Motrin), and Acetaminophen (Tylenol). (Acetaminophen is not accepted by all
persons to be an NSAID.) Although NSAIDs are generally a safe and effective
treatment method for pain, they have been associated with a number of
gastrointestinal problems including dyspepsia and gastric bleeding.
Lexaria postulates that delivery of NSAIDs through a lipid-based mechanism could
provide the beneficial properties of pain relief with lessened negative
gastrointestinal effects, and also potentially deliver lower dosages of active
ingredients with similar pain management outcomes as current pill forms at
higher dosages. ASA, Piroxicam, Diclofenac, Indomethacin, Ibruprofen, and
Acetaminophen are all named molecules in the latest Lexaria patent applications.
We do not have any current products under development in the space of NSAID
delivery with our technology, but we are investigating the best methods of
making this available to the marketplace. We are also examining whether we could
design and execute any in-vitro lab tests to begin generating real data as to
the bioavailability of NSAIDs with and without our protective technology.
Vitamins and Our Technology
Although there is little if any harm in the current delivery methodology for
most vitamins, it is also widely acknowledged that there is a great deal of
waste in current practices. Many vitamins are not efficiently absorbed by the GI
tract outside of their natural food sources. For this reason, those vitamins in
pill form are often in much, much higher dosages than is preferable. This is
done mostly because the vitamin industry is well aware that a large percentage
of the vitamin molecule is not absorbed. But beyond the waste of vitamins and
money, introduction of large volumes of vitamins can stress your liver and other
bodily functions.
The global vitamin and supplement market is worth $68 billion according to
Euromonitor. The category is both broad and deep, comprised of many popular and
some lesser known substances. Vitamins in general are thought to be an $8.5
billion annual market in the U.S. The U.S. is the largest single national market
in the world, and China and Japan are the 2nd and 3rd largest vitamin markets.
Vitamin E is fat soluble and can be incorporated into cell membranes which can
protect them from oxidative damage. Global consumption of natural source vitamin
E was 10,900 metric tons in 2013 worth $611.9 million.
Lexaria postulates that delivery of fat soluble vitamins through its patented
lipid-based delivery mechanism may result in less waste and lower dosages
required than most current pill forms. As well, ingestion of pills is an
unpleasant experience for many people so it is possible that vitamin delivery
through common food groups could vastly expand market demand for this sector.
Vitamin E is a named molecule in the latest Lexaria patent applications.
SOURCE: http://lexariaenergy.com/
Disclaimer
FN Media Group LLC (FNMG) owns and operates
FinancialNewsMedia.com (FNM)
which is a third party publisher that disseminates electronic information
through multiple online media channels. FNMG's intended purposes are to deliver
market updates and news alerts issued from private and publicly trading
companies as well as providing coverage and increased awareness for companies
that issue press to the public via online newswires. FNMG and its affiliated
companies are a news dissemination and financial marketing solutions provider
and are NOT a registered broker/dealer/analyst/adviser, holds no investment
licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's
market updates, news alerts and corporate profiles are NOT a solicitation or
recommendation to buy, sell or hold securities. The material in this release is
intended to be strictly informational and is NEVER to be construed or
interpreted as research material. All readers are strongly urged to perform
research and due diligence on their own and consult a licensed financial
professional before considering any level of investing in stocks. The companies
that are discussed in this release may or may not have approved the statements
made in this release. Information in this release is derived from a variety of
sources that may or may not include the referenced company's publicly
disseminated information. The accuracy or completeness of the information is not
warranted and is only as reliable as the sources from which it was obtained.
While this information is believed to be reliable, such reliability cannot be
guaranteed. FNMG disclaims any and all liability as to the completeness or
accuracy of the information contained and any omissions of material fact in this
release. This release may contain technical inaccuracies or typographical
errors. It is strongly recommended that any purchase or sale decision be
discussed with a financial adviser, or a broker-dealer, or a member of any
financial regulatory bodies. Investment in the securities of the companies
discussed in this release is highly speculative and carries a high degree of
risk. FNMG is not liable for any investment decisions by its readers or
subscribers. Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. This release is not without bias, and
is considered a conflict of interest if compensation has been received by FNMG
for its dissemination. To comply with Section 17(b) of the Securities Act of
1933, FNMG shall always disclose any compensation it has received, or expects to
receive in the future, for the dissemination of the information found herein on
behalf of one or more of the companies mentioned in this release. For current
services performed FNMG has been compensated two thousand dollars for Lexaria
Bioscience Corp. coverage by
a non affiliated 3rd party.
FNMG HOLDS NO SHARES OF Lexaria Bioscience Corp.
This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and FNMG undertakes no obligation to update such
statements.
|
